<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36899898</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>03</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2073-4409</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>5</Issue><PubDate><Year>2023</Year><Month>Feb</Month><Day>27</Day></PubDate></JournalIssue><Title>Cells</Title><ISOAbbreviation>Cells</ISOAbbreviation></Journal><ArticleTitle>The Neuroprotective Activities of the Novel Multi-Target Iron-Chelators in Models of Alzheimer's Disease, Amyotrophic Lateral Sclerosis and Aging.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">763</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/cells12050763</ELocationID><Abstract><AbstractText>The concept of chelation therapy as a valuable therapeutic approach in neurological disorders led us to develop multi-target, non-toxic, lipophilic, brain-permeable compounds with iron chelation and anti-apoptotic properties for neurodegenerative diseases, such as Parkinson's disease (PD), Alzheimer's disease (AD), age-related dementia and amyotrophic lateral sclerosis (ALS). Herein, we reviewed our two most effective such compounds, M30 and HLA20, based on a multimodal drug design paradigm. The compounds have been tested for their mechanisms of action using animal and cellular models such as APP/PS1 AD transgenic (Tg) mice, G93A-SOD1 mutant ALS Tg mice, C57BL/6 mice, Neuroblastoma &#xd7; Spinal Cord-34 (NSC-34) hybrid cells, a battery of behavior tests, and various immunohistochemical and biochemical techniques. These novel iron chelators exhibit neuroprotective activities by attenuating relevant neurodegenerative pathology, promoting positive behavior changes, and up-regulating neuroprotective signaling pathways. Taken together, these results suggest that our multifunctional iron-chelating compounds can upregulate several neuroprotective-adaptive mechanisms and pro-survival signaling pathways in the brain and might function as ideal drugs for neurodegenerative disorders, such as PD, AD, ALS, and aging-related cognitive decline, in which oxidative stress and iron-mediated toxicity and dysregulation of iron homeostasis have been implicated.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kupershmidt</LastName><ForeName>Lana</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Clinical Research Institute at Rambam Health Care, Haifa 31096, Israel.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Youdim</LastName><ForeName>Moussa B H</ForeName><Initials>MBH</Initials><AffiliationInfo><Affiliation>Technion-Rappaport Family Faculty of Medicine, Haifa 31096, Israel.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>02</Month><Day>27</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Cells</MedlineTA><NlmUniqueID>101600052</NlmUniqueID><ISSNLinking>2073-4409</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006912">Hydroxyquinolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007502">Iron Chelating Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>E1UOL152H7</RegistryNumber><NameOfSubstance UI="D007501">Iron</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000544" MajorTopicYN="Y">Alzheimer Disease</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="Y">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006912" MajorTopicYN="Y">Hydroxyquinolines</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008810" MajorTopicYN="N">Mice, Inbred C57BL</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007502" MajorTopicYN="N">Iron Chelating Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008822" MajorTopicYN="N">Mice, Transgenic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="Y">Parkinson Disease</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000375" MajorTopicYN="N">Aging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007501" MajorTopicYN="N">Iron</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Alzheimer&#x2019;s disease</Keyword><Keyword MajorTopicYN="N">amyloid precursor protein</Keyword><Keyword MajorTopicYN="N">amyotrophic lateral sclerosis</Keyword><Keyword MajorTopicYN="N">erythropoietin</Keyword><Keyword MajorTopicYN="N">iron</Keyword><Keyword MajorTopicYN="N">iron chelator</Keyword><Keyword MajorTopicYN="N">monoamine oxidase</Keyword><Keyword MajorTopicYN="N">neuroprotection</Keyword><Keyword MajorTopicYN="N">oxidative stress</Keyword><Keyword MajorTopicYN="N">tau protein</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>10</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>2</Month><Day>3</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2023</Year><Month>2</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>3</Month><Day>11</Day><Hour>1</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>3</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36899898</ArticleId><ArticleId IdType="pmc">PMC10001413</ArticleId><ArticleId IdType="doi">10.3390/cells12050763</ArticleId><ArticleId IdType="pii">cells12050763</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fang X., Zhang J., Roman R.J., Fan F. From 1901 to 2022, how far are we from truly understanding the pathogenesis of age-related dementia? Geroscience. 2022;44:1879&#x2013;1883. doi: 10.1007/s11357-022-00591-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11357-022-00591-7</ArticleId><ArticleId IdType="pmc">PMC9213583</ArticleId><ArticleId IdType="pubmed">35585301</ArticleId></ArticleIdList></Reference><Reference><Citation>Gotz M.E., Kunig G., Riederer P., Youdim M.B. Oxidative stress: Free radical production in neural degeneration. Pharmacol. Ther. 1994;63:37&#x2013;122. doi: 10.1016/0163-7258(94)90055-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0163-7258(94)90055-8</ArticleId><ArticleId IdType="pubmed">7972344</ArticleId></ArticleIdList></Reference><Reference><Citation>Halliwell B. Oxidative stress and neurodegeneration: Where are we now? J. Neurochem. 2006;97:1634&#x2013;1658. doi: 10.1111/j.1471-4159.2006.03907.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.03907.x</ArticleId><ArticleId IdType="pubmed">16805774</ArticleId></ArticleIdList></Reference><Reference><Citation>Benarroch E.E. Brain iron homeostasis and neurodegenerative disease. Neurology. 2009;72:1436&#x2013;1440. doi: 10.1212/WNL.0b013e3181a26b30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.0b013e3181a26b30</ArticleId><ArticleId IdType="pubmed">19380704</ArticleId></ArticleIdList></Reference><Reference><Citation>Rouault T.A., Cooperman S. Brain iron metabolism. Semin. Pediatr. Neurol. 2006;13:142&#x2013;148. doi: 10.1016/j.spen.2006.08.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.spen.2006.08.002</ArticleId><ArticleId IdType="pubmed">17101452</ArticleId></ArticleIdList></Reference><Reference><Citation>Moos T., Rosengren Nielsen T., Skjorringe T., Morgan E.H. Iron trafficking inside the brain. J. Neurochem. 2007;103:1730&#x2013;1740. doi: 10.1111/j.1471-4159.2007.04976.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2007.04976.x</ArticleId><ArticleId IdType="pubmed">17953660</ArticleId></ArticleIdList></Reference><Reference><Citation>Mattson M.P., Pedersen W.A., Duan W., Culmsee C., Camandola S. Cellular and molecular mechanisms underlying perturbed energy metabolism and neuronal degeneration in Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. Ann. N. Y. Acad. Sci. 1999;893:154&#x2013;175. doi: 10.1111/j.1749-6632.1999.tb07824.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.1999.tb07824.x</ArticleId><ArticleId IdType="pubmed">10672236</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartzokis G., Sultzer D., Mintz J., Holt L.E., Marx P., Phelan C.K., Marder S.R. In vivo evaluation of brain iron in Alzheimer&#x2019;s disease and normal subjects using MRI. Biol. Psychiatry. 1994;35:480&#x2013;487. doi: 10.1016/0006-3223(94)90047-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-3223(94)90047-7</ArticleId><ArticleId IdType="pubmed">8018799</ArticleId></ArticleIdList></Reference><Reference><Citation>Berg D., Gerlach M., Youdim M.B., Double K.L., Zecca L., Riederer P., Becker G. Brain iron pathways and their relevance to Parkinson&#x2019;s disease. J. Neurochem. 2001;79:225&#x2013;236. doi: 10.1046/j.1471-4159.2001.00608.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2001.00608.x</ArticleId><ArticleId IdType="pubmed">11677250</ArticleId></ArticleIdList></Reference><Reference><Citation>Zecca L., Youdim M.B., Riederer P., Connor J.R., Crichton R.R. Iron, brain ageing and neurodegenerative disorders. Nat. Rev. Neurosci. 2004;5:863&#x2013;873. doi: 10.1038/nrn1537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1537</ArticleId><ArticleId IdType="pubmed">15496864</ArticleId></ArticleIdList></Reference><Reference><Citation>Pratico D., Delanty N. Oxidative injury in diseases of the central nervous system: Focus on Alzheimer&#x2019;s disease. Am. J. Med. 2000;109:577&#x2013;585. doi: 10.1016/S0002-9343(00)00547-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9343(00)00547-7</ArticleId><ArticleId IdType="pubmed">11063960</ArticleId></ArticleIdList></Reference><Reference><Citation>Przedborski S. Programmed cell death in amyotrophic lateral sclerosis: A mechanism of pathogenic and therapeutic importance. Neurologist. 2004;10:1&#x2013;7. doi: 10.1097/01.nrl.0000106920.84668.37.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.nrl.0000106920.84668.37</ArticleId><ArticleId IdType="pubmed">14720310</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayre L.M., Smith M.A., Perry G. Chemistry and biochemistry of oxidative stress in neurodegenerative disease. Curr. Med. Chem. 2001;8:721&#x2013;738. doi: 10.2174/0929867013372922.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/0929867013372922</ArticleId><ArticleId IdType="pubmed">11375746</ArticleId></ArticleIdList></Reference><Reference><Citation>Altamura S., Muckenthaler M.U. Iron toxicity in diseases of aging: Alzheimer&#x2019;s disease, Parkinson&#x2019;s disease and atherosclerosis. J. Alzheimers Dis. 2009;16:879&#x2013;895. doi: 10.3233/JAD-2009-1010.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2009-1010</ArticleId><ArticleId IdType="pubmed">19387120</ArticleId></ArticleIdList></Reference><Reference><Citation>Riederer P., Dirr A., Goetz M., Sofic E., Jellinger K., Youdim M.B. Distribution of iron in different brain regions and subcellular compartments in Parkinson&#x2019;s disease. Ann. Neurol. 1992;32:S101&#x2013;S104. doi: 10.1002/ana.410320717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410320717</ArticleId><ArticleId IdType="pubmed">1510366</ArticleId></ArticleIdList></Reference><Reference><Citation>Youdim M.B. Brain iron deficiency and excess; cognitive impairment and neurodegeneration with involvement of striatum and hippocampus. Neurotox. Res. 2008;14:45&#x2013;56. doi: 10.1007/BF03033574.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF03033574</ArticleId><ArticleId IdType="pubmed">18790724</ArticleId></ArticleIdList></Reference><Reference><Citation>Youdim M.B., Buccafusco J.J. CNS Targets for multi-functional drugs in the treatment of Alzheimer&#x2019;s and Parkinson&#x2019;s diseases. J. Neural. Transm. 2005;112:519&#x2013;537. doi: 10.1007/s00702-004-0214-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00702-004-0214-z</ArticleId><ArticleId IdType="pubmed">15666041</ArticleId></ArticleIdList></Reference><Reference><Citation>Bullock R. SGS-742 Novartis. Curr. Opin. Investig. Drugs. 2005;6:108&#x2013;113.</Citation><ArticleIdList><ArticleId IdType="pubmed">15675610</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsolaki M., Kokarida K., Iakovidou V., Stilopoulos E., Meimaris J., Kazis A. Extrapyramidal symptoms and signs in Alzheimer&#x2019;s disease: Prevalence and correlation with the first symptom. Am. J. Alzheimers Dis. Other Demen. 2001;16:268&#x2013;278. doi: 10.1177/153331750101600512.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/153331750101600512</ArticleId><ArticleId IdType="pubmed">11603162</ArticleId></ArticleIdList></Reference><Reference><Citation>Schliebs R. Basal forebrain cholinergic dysfunction in Alzheimer&#x2019;s disease&#x2014;Interrelationship with beta-amyloid, inflammation and neurotrophin signaling. Neurochem. Res. 2005;30:895&#x2013;908. doi: 10.1007/s11064-005-6962-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-005-6962-9</ArticleId><ArticleId IdType="pubmed">16187224</ArticleId></ArticleIdList></Reference><Reference><Citation>Selkoe D.J., Schenk D. Alzheimer&#x2019;s disease: Molecular understanding predicts amyloid-based therapeutics. Annu. Rev. Pharmacol. Toxicol. 2003;43:545&#x2013;584. doi: 10.1146/annurev.pharmtox.43.100901.140248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.pharmtox.43.100901.140248</ArticleId><ArticleId IdType="pubmed">12415125</ArticleId></ArticleIdList></Reference><Reference><Citation>Joseph J.A., Shukitt-Hale B., Casadesus G. Reversing the deleterious effects of aging on neuronal communication and behavior: Beneficial properties of fruit polyphenolic compounds. Am. J. Clin. Nutr. 2005;81:313S&#x2013;316S. doi: 10.1093/ajcn/81.1.313S.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ajcn/81.1.313S</ArticleId><ArticleId IdType="pubmed">15640496</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J.T., Lahiri D.K. Metal and inflammatory targets for Alzheimer&#x2019;s disease. Curr. Drug Targets. 2004;5:535&#x2013;551. doi: 10.2174/1389450043345272.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/1389450043345272</ArticleId><ArticleId IdType="pubmed">15270200</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith M.A., Rottkamp C.A., Nunomura A., Raina A.K., Perry G. Oxidative stress in Alzheimer&#x2019;s disease. Biochim. Biophys. Acta. 2000;1502:139&#x2013;144. doi: 10.1016/S0925-4439(00)00040-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0925-4439(00)00040-5</ArticleId><ArticleId IdType="pubmed">10899439</ArticleId></ArticleIdList></Reference><Reference><Citation>Lovell M.A., Robertson J.D., Teesdale W.J., Campbell J.L., Markesbery W.R. Copper, iron and zinc in Alzheimer&#x2019;s disease senile plaques. J. Neurol. Sci. 1998;158:47&#x2013;52. doi: 10.1016/S0022-510X(98)00092-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0022-510X(98)00092-6</ArticleId><ArticleId IdType="pubmed">9667777</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinero D.J., Hu J., Connor J.R. Alterations in the interaction between iron regulatory proteins and their iron responsive element in normal and Alzheimer&#x2019;s diseased brains. Cell. Mol. Biol. 2000;46:761&#x2013;776.</Citation><ArticleIdList><ArticleId IdType="pubmed">10875438</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith M.A., Hirai K., Hsiao K., Pappolla M.A., Harris P.L., Siedlak S.L., Tabaton M., Perry G. Amyloid-beta deposition in Alzheimer transgenic mice is associated with oxidative stress. J. Neurochem. 1998;70:2212&#x2013;2215. doi: 10.1046/j.1471-4159.1998.70052212.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1998.70052212.x</ArticleId><ArticleId IdType="pubmed">9572310</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellani R.J., Moreira P.I., Liu G., Dobson J., Perry G., Smith M.A., Zhu X. Iron: The Redox-active center of oxidative stress in Alzheimer disease. Neurochem. Res. 2007;32:1640&#x2013;1645. doi: 10.1007/s11064-007-9360-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-007-9360-7</ArticleId><ArticleId IdType="pubmed">17508283</ArticleId></ArticleIdList></Reference><Reference><Citation>Honda K., Smith M.A., Zhu X., Baus D., Merrick W.C., Tartakoff A.M., Hattier T., Harris P.L., Siedlak S.L., Fujioka H., et al. Ribosomal RNA in Alzheimer disease is oxidized by bound redox-active iron. J. Biol. Chem. 2005;280:20978&#x2013;20986. doi: 10.1074/jbc.M500526200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M500526200</ArticleId><ArticleId IdType="pubmed">15767256</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreira P.I., Honda K., Liu Q., Santos M.S., Oliveira C.R., Aliev G., Nunomura A., Zhu X., Smith M.A., Perry G. Oxidative stress: The old enemy in Alzheimer&#x2019;s disease pathophysiology. Curr. Alzheimer Res. 2005;2:403&#x2013;408. doi: 10.2174/156720505774330537.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720505774330537</ArticleId><ArticleId IdType="pubmed">16248845</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith M.A., Harris P.L., Sayre L.M., Perry G. Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proc. Natl. Acad. Sci. USA. 1997;94:9866&#x2013;9868. doi: 10.1073/pnas.94.18.9866.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.94.18.9866</ArticleId><ArticleId IdType="pmc">PMC23283</ArticleId><ArticleId IdType="pubmed">9275217</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayre L.M., Perry G., Atwood C.S., Smith M.A. The role of metals in neurodegenerative diseases. Cell. Mol. Biol. 2000;46:731&#x2013;741.</Citation><ArticleIdList><ArticleId IdType="pubmed">10875436</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda A., Perry G., Abraham N.G., Dwyer B.E., Kutty R.K., Laitinen J.T., Petersen R.B., Smith M.A. Overexpression of heme oxygenase in neuronal cells, the possible interaction with Tau. J. Biol. Chem. 2000;275:5395&#x2013;5399. doi: 10.1074/jbc.275.8.5395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.275.8.5395</ArticleId><ArticleId IdType="pubmed">10681514</ArticleId></ArticleIdList></Reference><Reference><Citation>Shimohama S., Tanino H., Kawakami N., Okamura N., Kodama H., Yamaguchi T., Hayakawa T., Nunomura A., Chiba S., Perry G., et al. Activation of NADPH oxidase in Alzheimer&#x2019;s disease brains. Biochem. Biophys. Res. Commun. 2000;273:5&#x2013;9. doi: 10.1006/bbrc.2000.2897.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.2000.2897</ArticleId><ArticleId IdType="pubmed">10873554</ArticleId></ArticleIdList></Reference><Reference><Citation>Connor J.R., Menzies S.L., St Martin S.M., Mufson E.J. A histochemical study of iron, transferrin, and ferritin in Alzheimer&#x2019;s diseased brains. J. Neurosci. Res. 1992;31:75&#x2013;83. doi: 10.1002/jnr.490310111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.490310111</ArticleId><ArticleId IdType="pubmed">1613823</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith D.G., Cappai R., Barnham K.J. The redox chemistry of the Alzheimer&#x2019;s disease amyloid beta peptide. Biochim. Biophys. Acta. 2007;1768:1976&#x2013;1990. doi: 10.1016/j.bbamem.2007.02.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamem.2007.02.002</ArticleId><ArticleId IdType="pubmed">17433250</ArticleId></ArticleIdList></Reference><Reference><Citation>Smith M.A., Wehr K., Harris P.L., Siedlak S.L., Connor J.R., Perry G. Abnormal localization of iron regulatory protein in Alzheimer&#x2019;s disease. Brain Res. 1998;788:232&#x2013;236. doi: 10.1016/S0006-8993(98)00002-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-8993(98)00002-X</ArticleId><ArticleId IdType="pubmed">9555030</ArticleId></ArticleIdList></Reference><Reference><Citation>Schipper H.M. Heme oxygenase expression in human central nervous system disorders. Free Radic. Biol. Med. 2004;37:1995&#x2013;2011. doi: 10.1016/j.freeradbiomed.2004.09.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2004.09.015</ArticleId><ArticleId IdType="pubmed">15544918</ArticleId></ArticleIdList></Reference><Reference><Citation>Atamna H., Frey W.H., 2nd A role for heme in Alzheimer&#x2019;s disease: Heme binds amyloid beta and has altered metabolism. Proc. Natl. Acad. Sci. USA. 2004;101:11153&#x2013;11158. doi: 10.1073/pnas.0404349101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0404349101</ArticleId><ArticleId IdType="pmc">PMC503755</ArticleId><ArticleId IdType="pubmed">15263070</ArticleId></ArticleIdList></Reference><Reference><Citation>Loeffler D.A., Connor J.R., Juneau P.L., Snyder B.S., Kanaley L., DeMaggio A.J., Nguyen H., Brickman C.M., LeWitt P.A. Transferrin and iron in normal, Alzheimer&#x2019;s disease, and Parkinson&#x2019;s disease brain regions. J. Neurochem. 1995;65:710&#x2013;724. doi: 10.1046/j.1471-4159.1995.65020710.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1995.65020710.x</ArticleId><ArticleId IdType="pubmed">7616227</ArticleId></ArticleIdList></Reference><Reference><Citation>Zambenedetti P., De Bellis G., Biunno I., Musicco M., Zatta P. Transferrin C2 variant does confer a risk for Alzheimer&#x2019;s disease in caucasians. J. Alzheimers Dis. 2003;5:423&#x2013;427. doi: 10.3233/JAD-2003-5601.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2003-5601</ArticleId><ArticleId IdType="pubmed">14757931</ArticleId></ArticleIdList></Reference><Reference><Citation>Moalem S., Percy M.E., Andrews D.F., Kruck T.P., Wong S., Dalton A.J., Mehta P., Fedor B., Warren A.C. Are hereditary hemochromatosis mutations involved in Alzheimer disease? Am. J. Med. Genet. 2000;93:58&#x2013;66. doi: 10.1002/1096-8628(20000703)93:1&lt;58::AID-AJMG10&gt;3.0.CO;2-L.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1096-8628(20000703)93:1&lt;58::AID-AJMG10&gt;3.0.CO;2-L</ArticleId><ArticleId IdType="pubmed">10861683</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehmann D.J., Worwood M., Ellis R., Wimhurst V.L., Merryweather-Clarke A.T., Warden D.R., Smith A.D., Robson K.J. Iron genes, iron load and risk of Alzheimer&#x2019;s disease. J. Med. Genet. 2006;43:e52. doi: 10.1136/jmg.2006.040519.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jmg.2006.040519</ArticleId><ArticleId IdType="pmc">PMC2563163</ArticleId><ArticleId IdType="pubmed">17047092</ArticleId></ArticleIdList></Reference><Reference><Citation>Bush A.I. The metallobiology of Alzheimer&#x2019;s disease. Trends Neurosci. 2003;26:207&#x2013;214. doi: 10.1016/S0166-2236(03)00067-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0166-2236(03)00067-5</ArticleId><ArticleId IdType="pubmed">12689772</ArticleId></ArticleIdList></Reference><Reference><Citation>Rottkamp C.A., Raina A.K., Zhu X., Gaier E., Bush A.I., Atwood C.S., Chevion M., Perry G., Smith M.A. Redox-active iron mediates amyloid-beta toxicity. Free Radic. Biol. Med. 2001;30:447&#x2013;450. doi: 10.1016/S0891-5849(00)00494-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0891-5849(00)00494-9</ArticleId><ArticleId IdType="pubmed">11182300</ArticleId></ArticleIdList></Reference><Reference><Citation>Atwood C.S., Scarpa R.C., Huang X., Moir R.D., Jones W.D., Fairlie D.P., Tanzi R.E., Bush A.I. Characterization of copper interactions with alzheimer amyloid beta peptides: Identification of an attomolar-affinity copper binding site on amyloid beta1-42. J. Neurochem. 2000;75:1219&#x2013;1233. doi: 10.1046/j.1471-4159.2000.0751219.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2000.0751219.x</ArticleId><ArticleId IdType="pubmed">10936205</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J.T., Randall J.D., Cahill C.M., Eder P.S., Huang X., Gunshin H., Leiter L., McPhee J., Sarang S.S., Utsuki T., et al. An iron-responsive element type II in the 5&#x2032;-untranslated region of the Alzheimer&#x2019;s amyloid precursor protein transcript. J. Biol. Chem. 2002;277:45518&#x2013;45528. doi: 10.1074/jbc.M207435200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M207435200</ArticleId><ArticleId IdType="pubmed">12198135</ArticleId></ArticleIdList></Reference><Reference><Citation>Fillebeen C., Caltagirone A., Martelli A., Moulis J.M., Pantopoulos K. IRP1 Ser-711 is a phosphorylation site, critical for regulation of RNA-binding and aconitase activities. Biochem. J. 2005;388:143&#x2013;150. doi: 10.1042/BJ20041623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BJ20041623</ArticleId><ArticleId IdType="pmc">PMC1186702</ArticleId><ArticleId IdType="pubmed">15636585</ArticleId></ArticleIdList></Reference><Reference><Citation>McKie A.T., Marciani P., Rolfs A., Brennan K., Wehr K., Barrow D., Miret S., Bomford A., Peters T.J., Farzaneh F., et al. A novel duodenal iron-regulated transporter, IREG1, implicated in the basolateral transfer of iron to the circulation. Mol. Cell. 2000;5:299&#x2013;309. doi: 10.1016/S1097-2765(00)80425-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1097-2765(00)80425-6</ArticleId><ArticleId IdType="pubmed">10882071</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J.T., Bush A.I., Cho H.H., Smith D.H., Thomson A.M., Friedlich A.L., Lahiri D.K., Leedman P.J., Huang X., Cahill C.M. Iron and the translation of the amyloid precursor protein (APP) and ferritin mRNAs: Riboregulation against neural oxidative damage in Alzheimer&#x2019;s disease. Biochem. Soc. Trans. 2008;36:1282&#x2013;1287. doi: 10.1042/BST0361282.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST0361282</ArticleId><ArticleId IdType="pmc">PMC2746665</ArticleId><ArticleId IdType="pubmed">19021541</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers J., Cooper N.R., Webster S., Schultz J., McGeer P.L., Styren S.D., Civin W.H., Brachova L., Bradt B., Ward P., et al. Complement activation by beta-amyloid in Alzheimer disease. Proc. Natl. Acad. Sci. USA. 1992;89:10016&#x2013;10020. doi: 10.1073/pnas.89.21.10016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.89.21.10016</ArticleId><ArticleId IdType="pmc">PMC50268</ArticleId><ArticleId IdType="pubmed">1438191</ArticleId></ArticleIdList></Reference><Reference><Citation>Cho H.H., Cahill C.M., Vanderburg C.R., Scherzer C.R., Wang B., Huang X., Rogers J.T. Selective translational control of the Alzheimer amyloid precursor protein transcript by iron regulatory protein-1. J. Biol. Chem. 2010;285:31217&#x2013;31232. doi: 10.1074/jbc.M110.149161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.149161</ArticleId><ArticleId IdType="pmc">PMC2951196</ArticleId><ArticleId IdType="pubmed">20558735</ArticleId></ArticleIdList></Reference><Reference><Citation>Duce J.A., Tsatsanis A., Cater M.A., James S.A., Robb E., Wikhe K., Leong S.L., Perez K., Johanssen T., Greenough M.A., et al. Iron-export ferroxidase activity of beta-amyloid precursor protein is inhibited by zinc in Alzheimer&#x2019;s disease. Cell. 2010;142:857&#x2013;867. doi: 10.1016/j.cell.2010.08.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2010.08.014</ArticleId><ArticleId IdType="pmc">PMC2943017</ArticleId><ArticleId IdType="pubmed">20817278</ArticleId></ArticleIdList></Reference><Reference><Citation>Atwood C.S., Moir R.D., Huang X., Scarpa R.C., Bacarra N.M., Romano D.M., Hartshorn M.A., Tanzi R.E., Bush A.I. Dramatic aggregation of Alzheimer abeta by Cu(II) is induced by conditions representing physiological acidosis. J. Biol. Chem. 1998;273:12817&#x2013;12826. doi: 10.1074/jbc.273.21.12817.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.273.21.12817</ArticleId><ArticleId IdType="pubmed">9582309</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu S.T., Howlett G., Barrow C.J. Histidine-13 is a crucial residue in the zinc ion-induced aggregation of the A beta peptide of Alzheimer&#x2019;s disease. Biochemistry. 1999;38:9373&#x2013;9378. doi: 10.1021/bi990205o.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi990205o</ArticleId><ArticleId IdType="pubmed">10413512</ArticleId></ArticleIdList></Reference><Reference><Citation>House E., Collingwood J., Khan A., Korchazkina O., Berthon G., Exley C. Aluminium, iron, zinc and copper influence the in vitro formation of amyloid fibrils of Abeta42 in a manner which may have consequences for metal chelation therapy in Alzheimer&#x2019;s disease. J. Alzheimers Dis. 2004;6:291&#x2013;301. doi: 10.3233/JAD-2004-6310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2004-6310</ArticleId><ArticleId IdType="pubmed">15201484</ArticleId></ArticleIdList></Reference><Reference><Citation>Monji A., Utsumi H., Ueda T., Imoto T., Yoshida I., Hashioka S., Tashiro K., Tashiro N. Amyloid-beta-protein (A beta) (25-35)-associated free radical generation is strongly influenced by the aggregational state of the peptides. Life Sci. 2002;70:833&#x2013;841. doi: 10.1016/S0024-3205(01)01451-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0024-3205(01)01451-5</ArticleId><ArticleId IdType="pubmed">11833745</ArticleId></ArticleIdList></Reference><Reference><Citation>Atwood C.S., Obrenovich M.E., Liu T., Chan H., Perry G., Smith M.A., Martins R.N. Amyloid-beta: A chameleon walking in two worlds: A review of the trophic and toxic properties of amyloid-beta. Brain Res. Brain Res. Rev. 2003;43:1&#x2013;16. doi: 10.1016/S0165-0173(03)00174-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-0173(03)00174-7</ArticleId><ArticleId IdType="pubmed">14499458</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu X., Raina A.K., Lee H.G., Casadesus G., Smith M.A., Perry G. Oxidative stress signalling in Alzheimer&#x2019;s disease. Brain Res. 2004;1000:32&#x2013;39. doi: 10.1016/j.brainres.2004.01.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2004.01.012</ArticleId><ArticleId IdType="pubmed">15053949</ArticleId></ArticleIdList></Reference><Reference><Citation>Castellani R.J., Honda K., Zhu X., Cash A.D., Nunomura A., Perry G., Smith M.A. Contribution of redox-active iron and copper to oxidative damage in Alzheimer disease. Ageing Res. Rev. 2004;3:319&#x2013;326. doi: 10.1016/j.arr.2004.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arr.2004.01.002</ArticleId><ArticleId IdType="pubmed">15231239</ArticleId></ArticleIdList></Reference><Reference><Citation>D&#x2019;Andrea M.R., Nagele R.G., Wang H.Y., Peterson P.A., Lee D.H. Evidence that neurones accumulating amyloid can undergo lysis to form amyloid plaques in Alzheimer&#x2019;s disease. Histopathology. 2001;38:120&#x2013;134. doi: 10.1046/j.1365-2559.2001.01082.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2559.2001.01082.x</ArticleId><ArticleId IdType="pubmed">11207825</ArticleId></ArticleIdList></Reference><Reference><Citation>Frackowiak J., Miller D.L., Potempska A., Sukontasup T., Mazur-Kolecka B. Secretion and accumulation of Abeta by brain vascular smooth muscle cells from AbetaPP-Swedish transgenic mice. J. Neuropathol. Exp. Neurol. 2003;62:685&#x2013;696. doi: 10.1093/jnen/62.6.685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/62.6.685</ArticleId><ArticleId IdType="pubmed">12834113</ArticleId></ArticleIdList></Reference><Reference><Citation>Gouras G.K., Tsai J., Naslund J., Vincent B., Edgar M., Checler F., Greenfield J.P., Haroutunian V., Buxbaum J.D., Xu H., et al. Intraneuronal Abeta42 accumulation in human brain. Am. J. Pathol. 2000;156:15&#x2013;20. doi: 10.1016/S0002-9440(10)64700-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)64700-1</ArticleId><ArticleId IdType="pmc">PMC1868613</ArticleId><ArticleId IdType="pubmed">10623648</ArticleId></ArticleIdList></Reference><Reference><Citation>Verdile G., Fuller S., Atwood C.S., Laws S.M., Gandy S.E., Martins R.N. The role of beta amyloid in Alzheimer&#x2019;s disease: Still a cause of everything or the only one who got caught? Pharmacol. Res. 2004;50:397&#x2013;409. doi: 10.1016/j.phrs.2003.12.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2003.12.028</ArticleId><ArticleId IdType="pubmed">15304237</ArticleId></ArticleIdList></Reference><Reference><Citation>Schubert D., Chevion M. The role of iron in beta amyloid toxicity. Biochem. Biophys. Res. Commun. 1995;216:702&#x2013;707. doi: 10.1006/bbrc.1995.2678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.1995.2678</ArticleId><ArticleId IdType="pubmed">7488167</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuajungco M.P., Goldstein L.E., Nunomura A., Smith M.A., Lim J.T., Atwood C.S., Huang X., Farrag Y.W., Perry G., Bush A.I. Evidence that the beta-amyloid plaques of Alzheimer&#x2019;s disease represent the redox-silencing and entombment of abeta by zinc. J. Biol. Chem. 2000;275:19439&#x2013;19442. doi: 10.1074/jbc.C000165200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.C000165200</ArticleId><ArticleId IdType="pubmed">10801774</ArticleId></ArticleIdList></Reference><Reference><Citation>Robinson S.R., Bishop G.M. Abeta as a bioflocculant: Implications for the amyloid hypothesis of Alzheimer&#x2019;s disease. Neurobiol. Aging. 2002;23:1051&#x2013;1072. doi: 10.1016/S0197-4580(01)00342-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0197-4580(01)00342-6</ArticleId><ArticleId IdType="pubmed">12470802</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu B., Moloney A., Meehan S., Morris K., Thomas S.E., Serpell L.C., Hider R., Marciniak S.J., Lomas D.A., Crowther D.C. Iron promotes the toxicity of amyloid beta peptide by impeding its ordered aggregation. J. Biol. Chem. 2011;286:4248&#x2013;4256. doi: 10.1074/jbc.M110.158980.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.158980</ArticleId><ArticleId IdType="pmc">PMC3039358</ArticleId><ArticleId IdType="pubmed">21147772</ArticleId></ArticleIdList></Reference><Reference><Citation>Good P.F., Perl D.P., Bierer L.M., Schmeidler J. Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer&#x2019;s disease: A laser microprobe (LAMMA) study. Ann. Neurol. 1992;31:286&#x2013;292. doi: 10.1002/ana.410310310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.410310310</ArticleId><ArticleId IdType="pubmed">1637136</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis P.T., Palmer A.M., Snape M., Wilcock G.K. The cholinergic hypothesis of Alzheimer&#x2019;s disease: A review of progress. J. Neurol. Neurosurg. Psychiatry. 1999;66:137&#x2013;147. doi: 10.1136/jnnp.66.2.137.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.66.2.137</ArticleId><ArticleId IdType="pmc">PMC1736202</ArticleId><ArticleId IdType="pubmed">10071091</ArticleId></ArticleIdList></Reference><Reference><Citation>Giacobini E. Long-term stabilizing effect of cholinesterase inhibitors in the therapy of Alzheimer&#x2019;s disease. J. Neural. Transm. Suppl. 2002;62:181&#x2013;187. doi: 10.1007/978-3-7091-6139-5_17.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-7091-6139-5_17</ArticleId><ArticleId IdType="pubmed">12456062</ArticleId></ArticleIdList></Reference><Reference><Citation>Lopez O.L., Becker J.T., Wisniewski S., Saxton J., Kaufer D.I., DeKosky S.T. Cholinesterase inhibitor treatment alters the natural history of Alzheimer&#x2019;s disease. J. Neurol. Neurosurg. Psychiatry. 2002;72:310&#x2013;314. doi: 10.1136/jnnp.72.3.310.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.72.3.310</ArticleId><ArticleId IdType="pmc">PMC1737770</ArticleId><ArticleId IdType="pubmed">11861686</ArticleId></ArticleIdList></Reference><Reference><Citation>Racchi M., Mazzucchelli M., Porrello E., Lanni C., Govoni S. Acetylcholinesterase inhibitors: Novel activities of old molecules. Pharmacol. Res. 2004;50:441&#x2013;451. doi: 10.1016/j.phrs.2003.12.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2003.12.027</ArticleId><ArticleId IdType="pubmed">15304241</ArticleId></ArticleIdList></Reference><Reference><Citation>Francis P.T., Nordberg A., Arnold S.E. A preclinical view of cholinesterase inhibitors in neuroprotection: Do they provide more than symptomatic benefits in Alzheimer&#x2019;s disease? Trends Pharmacol. Sci. 2005;26:104&#x2013;111. doi: 10.1016/j.tips.2004.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2004.12.010</ArticleId><ArticleId IdType="pubmed">15681028</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang X., Moir R.D., Tanzi R.E., Bush A.I., Rogers J.T. Redox-active metals, oxidative stress, and Alzheimer&#x2019;s disease pathology. Ann. N. Y. Acad. Sci. 2004;1012:153&#x2013;163. doi: 10.1196/annals.1306.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1306.012</ArticleId><ArticleId IdType="pubmed">15105262</ArticleId></ArticleIdList></Reference><Reference><Citation>Bolognin S., Drago D., Messori L., Zatta P. Chelation therapy for neurodegenerative diseases. Med. Res. Rev. 2009;29:547&#x2013;570. doi: 10.1002/med.20148.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/med.20148</ArticleId><ArticleId IdType="pubmed">19177468</ArticleId></ArticleIdList></Reference><Reference><Citation>Hider R.C., Ma Y., Molina-Holgado F., Gaeta A., Roy S. Iron chelation as a potential therapy for neurodegenerative disease. Biochem. Soc. Trans. 2008;36:1304&#x2013;1308. doi: 10.1042/BST0361304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/BST0361304</ArticleId><ArticleId IdType="pubmed">19021545</ArticleId></ArticleIdList></Reference><Reference><Citation>Molina-Holgado F., Hider R.C., Gaeta A., Williams R., Francis P. Metals ions and neurodegeneration. Biometals. 2007;20:639&#x2013;654. doi: 10.1007/s10534-006-9033-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10534-006-9033-z</ArticleId><ArticleId IdType="pubmed">17294125</ArticleId></ArticleIdList></Reference><Reference><Citation>Whitnall M., Richardson D.R. Iron: A new target for pharmacological intervention in neurodegenerative diseases. Semin. Pediatr. Neurol. 2006;13:186&#x2013;197. doi: 10.1016/j.spen.2006.08.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.spen.2006.08.008</ArticleId><ArticleId IdType="pubmed">17101458</ArticleId></ArticleIdList></Reference><Reference><Citation>Zatta P., Drago D., Bolognin S., Sensi S.L. Alzheimer&#x2019;s disease, metal ions and metal homeostatic therapy. Trends Pharmacol. Sci. 2009;30:346&#x2013;355. doi: 10.1016/j.tips.2009.05.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2009.05.002</ArticleId><ArticleId IdType="pubmed">19540003</ArticleId></ArticleIdList></Reference><Reference><Citation>Crapper McLachlan D.R., Dalton A.J., Kruck T.P., Bell M.Y., Smith W.L., Kalow W., Andrews D.F. Intramuscular desferrioxamine in patients with Alzheimer&#x2019;s disease. Lancet. 1991;337:1304&#x2013;1308. doi: 10.1016/0140-6736(91)92978-B.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0140-6736(91)92978-B</ArticleId><ArticleId IdType="pubmed">1674295</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherny R.A., Legg J.T., McLean C.A., Fairlie D.P., Huang X., Atwood C.S., Beyreuther K., Tanzi R.E., Masters C.L., Bush A.I. Aqueous dissolution of Alzheimer&#x2019;s disease Abeta amyloid deposits by biometal depletion. J. Biol. Chem. 1999;274:23223&#x2013;23228. doi: 10.1074/jbc.274.33.23223.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.274.33.23223</ArticleId><ArticleId IdType="pubmed">10438495</ArticleId></ArticleIdList></Reference><Reference><Citation>Cahoon L. The curious case of clioquinol. Nat. Med. 2009;15:356&#x2013;359. doi: 10.1038/nm0409-356.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm0409-356</ArticleId><ArticleId IdType="pubmed">19350001</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenagaratnam L., McShane R. Clioquinol for the treatment of Alzheimer&#x2019;s Disease. Cochrane Database Syst. Rev. 2006;25:CD005380. doi: 10.1002/14651858.CD005380.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD005380.pub2</ArticleId><ArticleId IdType="pubmed">16437529</ArticleId></ArticleIdList></Reference><Reference><Citation>Sampson E., Jenagaratnam L., McShane R. Metal protein attenuating compounds for the treatment of Alzheimer&#x2019;s disease. Cochrane Database Syst. Rev. 2008;21:CD005380. doi: 10.1002/14651858.CD005380.pub3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD005380.pub3</ArticleId><ArticleId IdType="pubmed">18254079</ArticleId></ArticleIdList></Reference><Reference><Citation>Bush A.I. Drug development based on the metals hypothesis of Alzheimer&#x2019;s disease. J. Alzheimers Dis. 2008;15:223&#x2013;240. doi: 10.3233/JAD-2008-15208.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2008-15208</ArticleId><ArticleId IdType="pubmed">18953111</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritchie C.W., Bush A.I., Mackinnon A., Macfarlane S., Mastwyk M., MacGregor L., Kiers L., Cherny R., Li Q.X., Tammer A., et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: A pilot phase 2 clinical trial. Arch. Neurol. 2003;60:1685&#x2013;1691. doi: 10.1001/archneur.60.12.1685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.60.12.1685</ArticleId><ArticleId IdType="pubmed">14676042</ArticleId></ArticleIdList></Reference><Reference><Citation>Faux N.G., Ritchie C.W., Gunn A., Rembach A., Tsatsanis A., Bedo J., Harrison J., Lannfelt L., Blennow K., Zetterberg H., et al. PBT2 rapidly improves cognition in Alzheimer&#x2019;s Disease: Additional phase II analyses. J. Alzheimers Dis. 2010;20:509&#x2013;516. doi: 10.3233/JAD-2010-1390.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-1390</ArticleId><ArticleId IdType="pubmed">20164561</ArticleId></ArticleIdList></Reference><Reference><Citation>Cherny R.A., Atwood C.S., Xilinas M.E., Gray D.N., Jones W.D., McLean C.A., Barnham K.J., Volitakis I., Fraser F.W., Kim Y., et al. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer&#x2019;s disease transgenic mice. Neuron. 2001;30:665&#x2013;676. doi: 10.1016/S0896-6273(01)00317-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0896-6273(01)00317-8</ArticleId><ArticleId IdType="pubmed">11430801</ArticleId></ArticleIdList></Reference><Reference><Citation>Mancino A.M., Hindo S.S., Kochi A., Lim M.H. Effects of clioquinol on metal-triggered amyloid-beta aggregation revisited. Inorg. Chem. 2009;48:9596&#x2013;9598. doi: 10.1021/ic9014256.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/ic9014256</ArticleId><ArticleId IdType="pubmed">19817493</ArticleId></ArticleIdList></Reference><Reference><Citation>Morse L.J., Payton S.M., Cuny G.D., Rogers J.T. FDA-preapproved drugs targeted to the translational regulation and processing of the amyloid precursor protein. J. Mol. Neurosci. 2004;24:129&#x2013;136. doi: 10.1385/JMN:24:1:129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/JMN:24:1:129</ArticleId><ArticleId IdType="pubmed">15314261</ArticleId></ArticleIdList></Reference><Reference><Citation>Payton S., Cahill C.M., Randall J.D., Gullans S.R., Rogers J.T. Drug discovery targeted to the Alzheimer&#x2019;s APP mRNA 5&#x2032;-untranslated region: The action of paroxetine and dimercaptopropanol. J. Mol. Neurosci. 2003;20:267&#x2013;275. doi: 10.1385/JMN:20:3:267.</Citation><ArticleIdList><ArticleId IdType="doi">10.1385/JMN:20:3:267</ArticleId><ArticleId IdType="pubmed">14501007</ArticleId></ArticleIdList></Reference><Reference><Citation>Dedeoglu A., Cormier K., Payton S., Tseitlin K.A., Kremsky J.N., Lai L., Li X., Moir R.D., Tanzi R.E., Bush A.I., et al. Preliminary studies of a novel bifunctional metal chelator targeting Alzheimer&#x2019;s amyloidogenesis. Exp. Gerontol. 2004;39:1641&#x2013;1649. doi: 10.1016/j.exger.2004.08.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exger.2004.08.016</ArticleId><ArticleId IdType="pubmed">15582280</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalli A., Bolognesi M.L., Minarini A., Rosini M., Tumiatti V., Recanatini M., Melchiorre C. Multi-target-directed ligands to combat neurodegenerative diseases. J. Med. Chem. 2008;51:347&#x2013;372. doi: 10.1021/jm7009364.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm7009364</ArticleId><ArticleId IdType="pubmed">18181565</ArticleId></ArticleIdList></Reference><Reference><Citation>Mandel S., Amit T., Bar-Am O., Youdim M.B. Iron dysregulation in Alzheimer&#x2019;s disease: Multimodal brain permeable iron chelating drugs, possessing neuroprotective-neurorescue and amyloid precursor protein-processing regulatory activities as therapeutic agents. Prog. Neurobiol. 2007;82:348&#x2013;360. doi: 10.1016/j.pneurobio.2007.06.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pneurobio.2007.06.001</ArticleId><ArticleId IdType="pubmed">17659826</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Schyf C.J., Geldenhuys W.J., Youdim M.B. Multifunctional drugs with different CNS targets for neuropsychiatric disorders. J. Neurochem. 2006;99:1033&#x2013;1048. doi: 10.1111/j.1471-4159.2006.04141.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.04141.x</ArticleId><ArticleId IdType="pubmed">17054441</ArticleId></ArticleIdList></Reference><Reference><Citation>Van der Schyf C.J., Mandel S., Geldenhuys W.J., Amit T., Avramovich Y., Zheng H., Fridkin M., Gal S., Weinreb O., Bar Am O., et al. Novel multifunctional anti-Alzheimer drugs with various CNS neurotransmitter targets and neuroprotective moieties. Curr. Alzheimer Res. 2007;4:522&#x2013;536. doi: 10.2174/156720507783018226.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720507783018226</ArticleId><ArticleId IdType="pubmed">18220515</ArticleId></ArticleIdList></Reference><Reference><Citation>Youdim M.B., Buccafusco J.J. Multi-functional drugs for various CNS targets in the treatment of neurodegenerative disorders. Trends Pharmacol. Sci. 2005;26:27&#x2013;35. doi: 10.1016/j.tips.2004.11.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.tips.2004.11.007</ArticleId><ArticleId IdType="pubmed">15629202</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang H.Y. One-compound-multiple-targets strategy to combat Alzheimer&#x2019;s disease. FEBS Lett. 2005;579:5260&#x2013;5264. doi: 10.1016/j.febslet.2005.09.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.febslet.2005.09.006</ArticleId><ArticleId IdType="pubmed">16194540</ArticleId></ArticleIdList></Reference><Reference><Citation>Swerdlow R.H. Brain aging, Alzheimer&#x2019;s disease, and mitochondria. Biochim. Biophys. Acta. 2011;1812:1630&#x2013;1639. doi: 10.1016/j.bbadis.2011.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbadis.2011.08.012</ArticleId><ArticleId IdType="pmc">PMC3210037</ArticleId><ArticleId IdType="pubmed">21920438</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin W.R., Ye F.Q., Allen P.S. Increasing striatal iron content associated with normal aging. Mov. Disord. 1998;13:281&#x2013;286. doi: 10.1002/mds.870130214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mds.870130214</ArticleId><ArticleId IdType="pubmed">9539342</ArticleId></ArticleIdList></Reference><Reference><Citation>Connor J.R., Snyder B.S., Arosio P., Loeffler D.A., LeWitt P. A quantitative analysis of isoferritins in select regions of aged, parkinsonian, and Alzheimer&#x2019;s diseased brains. J. Neurochem. 1995;65:717&#x2013;724. doi: 10.1046/j.1471-4159.1995.65020717.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.1995.65020717.x</ArticleId><ArticleId IdType="pubmed">7616228</ArticleId></ArticleIdList></Reference><Reference><Citation>Benkovic S.A., Connor J.R. Ferritin, transferrin, and iron in selected regions of the adult and aged rat brain. J. Comp. Neurol. 1993;338:97&#x2013;113. doi: 10.1002/cne.903380108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cne.903380108</ArticleId><ArticleId IdType="pubmed">8300902</ArticleId></ArticleIdList></Reference><Reference><Citation>House M.J., St Pierre T.G., Milward E.A., Bruce D.G., Olynyk J.K. Relationship between brain R(2) and liver and serum iron concentrations in elderly men. Magn. Reson. Med. 2010;63:275&#x2013;281. doi: 10.1002/mrm.22263.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mrm.22263</ArticleId><ArticleId IdType="pubmed">20099321</ArticleId></ArticleIdList></Reference><Reference><Citation>Cronin S., Berger S., Ding J., Schymick J.C., Washecka N., Hernandez D.G., Greenway M.J., Bradley D.G., Traynor B.J., Hardiman O. A genome-wide association study of sporadic ALS in a homogenous Irish population. Hum. Mol. Genet. 2008;17:768&#x2013;774. doi: 10.1093/hmg/ddm361.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddm361</ArticleId><ArticleId IdType="pubmed">18057069</ArticleId></ArticleIdList></Reference><Reference><Citation>Valdmanis P.N., Daoud H., Dion P.A., Rouleau G.A. Recent advances in the genetics of amyotrophic lateral sclerosis. Curr. Neurol. Neurosci. Rep. 2009;9:198&#x2013;205. doi: 10.1007/s11910-009-0030-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11910-009-0030-9</ArticleId><ArticleId IdType="pubmed">19348708</ArticleId></ArticleIdList></Reference><Reference><Citation>Cozzolino M., Ferri A., Carri M.T. Amyotrophic lateral sclerosis: From current developments in the laboratory to clinical implications. Antioxid. Redox Signal. 2008;10:405&#x2013;443. doi: 10.1089/ars.2007.1760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2007.1760</ArticleId><ArticleId IdType="pubmed">18370853</ArticleId></ArticleIdList></Reference><Reference><Citation>Urushitani M., Ezzi S.A., Julien J.P. Therapeutic effects of immunization with mutant superoxide dismutase in mice models of amyotrophic lateral sclerosis. Proc. Natl. Acad. Sci. USA. 2007;104:2495&#x2013;2500. doi: 10.1073/pnas.0606201104.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.0606201104</ArticleId><ArticleId IdType="pmc">PMC1790867</ArticleId><ArticleId IdType="pubmed">17277077</ArticleId></ArticleIdList></Reference><Reference><Citation>Carri M.T., Ferri A., Cozzolino M., Calabrese L., Rotilio G. Neurodegeneration in amyotrophic lateral sclerosis: The role of oxidative stress and altered homeostasis of metals. Brain Res. Bull. 2003;61:365&#x2013;374. doi: 10.1016/S0361-9230(03)00179-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0361-9230(03)00179-5</ArticleId><ArticleId IdType="pubmed">12909279</ArticleId></ArticleIdList></Reference><Reference><Citation>Liochev S.I., Fridovich I. The role of O2.- in the production of HO.: In vitro and in vivo. Free Radic. Biol. Med. 1994;16:29&#x2013;33. doi: 10.1016/0891-5849(94)90239-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0891-5849(94)90239-9</ArticleId><ArticleId IdType="pubmed">8299992</ArticleId></ArticleIdList></Reference><Reference><Citation>Imon Y., Yamaguchi S., Yamamura Y., Tsuji S., Kajima T., Ito K., Nakamura S. Low intensity areas observed on T2-weighted magnetic resonance imaging of the cerebral cortex in various neurological diseases. J. Neurol. Sci. 1995;134:27&#x2013;32. doi: 10.1016/0022-510X(95)00205-G.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(95)00205-G</ArticleId><ArticleId IdType="pubmed">8847542</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasarskis E.J., Tandon L., Lovell M.A., Ehmann W.D. Aluminum, calcium, and iron in the spinal cord of patients with sporadic amyotrophic lateral sclerosis using laser microprobe mass spectroscopy: A preliminary study. J. Neurol. Sci. 1995;130:203&#x2013;208. doi: 10.1016/0022-510X(95)00037-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0022-510X(95)00037-3</ArticleId><ArticleId IdType="pubmed">8586987</ArticleId></ArticleIdList></Reference><Reference><Citation>Oba H., Araki T., Ohtomo K., Monzawa S., Uchiyama G., Koizumi K., Nogata Y., Kachi K., Shiozawa Z., Kobayashi M. Amyotrophic lateral sclerosis: T2 shortening in motor cortex at MR imaging. Radiology. 1993;189:843&#x2013;846. doi: 10.1148/radiology.189.3.8234713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1148/radiology.189.3.8234713</ArticleId><ArticleId IdType="pubmed">8234713</ArticleId></ArticleIdList></Reference><Reference><Citation>Danzeisen R., Achsel T., Bederke U., Cozzolino M., Crosio C., Ferri A., Frenzel M., Gralla E.B., Huber L., Ludolph A., et al. Superoxide dismutase 1 modulates expression of transferrin receptor. J. Biol. Inorg. Chem. 2006;11:489&#x2013;498. doi: 10.1007/s00775-006-0099-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00775-006-0099-4</ArticleId><ArticleId IdType="pubmed">16680451</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuno Y., Amari M., Takatama M., Aizawa H., Mihara B., Okamoto K. Transferrin localizes in Bunina bodies in amyotrophic lateral sclerosis. Acta Neuropathol. 2006;112:597&#x2013;603. doi: 10.1007/s00401-006-0122-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00401-006-0122-4</ArticleId><ArticleId IdType="pubmed">16896902</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong S.Y., Rathore K.I., Schulz K., Ponka P., Arosio P., David S. Dysregulation of iron homeostasis in the CNS contributes to disease progression in a mouse model of amyotrophic lateral sclerosis. J. Neurosci. 2009;29:610&#x2013;619. doi: 10.1523/JNEUROSCI.5443-08.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.5443-08.2009</ArticleId><ArticleId IdType="pmc">PMC6665152</ArticleId><ArticleId IdType="pubmed">19158288</ArticleId></ArticleIdList></Reference><Reference><Citation>Sutedja N.A., Sinke R.J., Van Vught P.W., Van der Linden M.W., Wokke J.H., Van Duijn C.M., Njajou O.T., Van der Schouw Y.T., Veldink J.H., Van den Berg L.H. The association between H63D mutations in HFE and amyotrophic lateral sclerosis in a Dutch population. Arch. Neurol. 2007;64:63&#x2013;67. doi: 10.1001/archneur.64.1.63.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archneur.64.1.63</ArticleId><ArticleId IdType="pubmed">17210810</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang X.S., Lee S., Simmons Z., Boyer P., Scott K., Liu W., Connor J. Increased incidence of the Hfe mutation in amyotrophic lateral sclerosis and related cellular consequences. J. Neurol. Sci. 2004;227:27&#x2013;33. doi: 10.1016/j.jns.2004.08.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2004.08.003</ArticleId><ArticleId IdType="pubmed">15546588</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller R.G., Mitchell J.D., Lyon M., Moore D.H. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) Cochrane Database Syst. Rev. 2007:CD001447. doi: 10.1002/14651858.CD001447.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD001447.pub2</ArticleId><ArticleId IdType="pubmed">17253460</ArticleId></ArticleIdList></Reference><Reference><Citation>Crow J.P., Calingasan N.Y., Chen J., Hill J.L., Beal M.F. Manganese porphyrin given at symptom onset markedly extends survival of ALS mice. Ann. Neurol. 2005;58:258&#x2013;265. doi: 10.1002/ana.20552.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20552</ArticleId><ArticleId IdType="pubmed">16049935</ArticleId></ArticleIdList></Reference><Reference><Citation>Kriz J., Nguyen M.D., Julien J.P. Minocycline slows disease progression in a mouse model of amyotrophic lateral sclerosis. Neurobiol. Dis. 2002;10:268&#x2013;278. doi: 10.1006/nbdi.2002.0487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/nbdi.2002.0487</ArticleId><ArticleId IdType="pubmed">12270689</ArticleId></ArticleIdList></Reference><Reference><Citation>Waibel S., Reuter A., Malessa S., Blaugrund E., Ludolph A.C. Rasagiline alone and in combination with riluzole prolongs survival in an ALS mouse model. J. Neurol. 2004;251:1080&#x2013;1084. doi: 10.1007/s00415-004-0481-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-004-0481-5</ArticleId><ArticleId IdType="pubmed">15372249</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H., Weiner L.M., Bar-Am O., Epsztejn S., Cabantchik Z.I., Warshawsky A., Youdim M.B., Fridkin M. Design, synthesis, and evaluation of novel bifunctional iron-chelators as potential agents for neuroprotection in Alzheimer&#x2019;s, Parkinson&#x2019;s, and other neurodegenerative diseases. Bioorg. Med. Chem. 2005;13:773&#x2013;783. doi: 10.1016/j.bmc.2004.10.037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bmc.2004.10.037</ArticleId><ArticleId IdType="pubmed">15653345</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng H., Gal S., Weiner L.M., Bar-Am O., Warshawsky A., Fridkin M., Youdim M.B. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases: In vitro studies on antioxidant activity, prevention of lipid peroxide formation and monoamine oxidase inhibition. J. Neurochem. 2005;95:68&#x2013;78. doi: 10.1111/j.1471-4159.2005.03340.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03340.x</ArticleId><ArticleId IdType="pubmed">16181413</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreb O., Amit T., Mandel S., Kupershmidt L., Youdim M.B. Neuroprotective multifunctional iron chelators: From redox-sensitive process to novel therapeutic opportunities. Antioxid. Redox Signal. 2010;13:919&#x2013;949. doi: 10.1089/ars.2009.2929.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2009.2929</ArticleId><ArticleId IdType="pubmed">20095867</ArticleId></ArticleIdList></Reference><Reference><Citation>Avramovich-Tirosh Y., Reznichenko L., Mit T., Zheng H., Fridkin M., Weinreb O., Mandel S., Youdim M.B. Neurorescue activity, APP regulation and amyloid-beta peptide reduction by novel multi-functional brain permeable iron- chelating- antioxidants, M-30 and green tea polyphenol, EGCG. Curr. Alzheimer Res. 2007;4:403&#x2013;411. doi: 10.2174/156720507781788927.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720507781788927</ArticleId><ArticleId IdType="pubmed">17908043</ArticleId></ArticleIdList></Reference><Reference><Citation>Avramovich-Tirosh Y., Amit T., Bar-Am O., Zheng H., Fridkin M., Youdim M.B. Therapeutic targets and potential of the novel brain-permeable multifunctional iron chelator-monoamine oxidase inhibitor drug, M-30, for the treatment of Alzheimer&#x2019;s disease. J. Neurochem. 2007;100:490&#x2013;502. doi: 10.1111/j.1471-4159.2006.04258.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.04258.x</ArticleId><ArticleId IdType="pubmed">17144902</ArticleId></ArticleIdList></Reference><Reference><Citation>Gal S., Zheng H., Fridkin M., Youdim M.B. Novel multifunctional neuroprotective iron chelator-monoamine oxidase inhibitor drugs for neurodegenerative diseases. In vivo selective brain monoamine oxidase inhibition and prevention of MPTP-induced striatal dopamine depletion. J. Neurochem. 2005;95:79&#x2013;88. doi: 10.1111/j.1471-4159.2005.03341.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2005.03341.x</ArticleId><ArticleId IdType="pubmed">16181414</ArticleId></ArticleIdList></Reference><Reference><Citation>Gal S., Zheng H., Fridkin M., Youdim M.B. Restoration of nigrostriatal dopamine neurons in post-MPTP treatment by the novel multifunctional brain-permeable iron chelator-monoamine oxidase inhibitor drug, M30. Neurotox. Res. 2010;17:15&#x2013;27. doi: 10.1007/s12640-009-9070-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12640-009-9070-9</ArticleId><ArticleId IdType="pubmed">19609632</ArticleId></ArticleIdList></Reference><Reference><Citation>Avramovich-Tirosh Y., Bar-Am O., Amit T., Youdim M.B., Weinreb O. Up-regulation of hypoxia-inducible factor (HIF)-1alpha and HIF-target genes in cortical neurons by the novel multifunctional iron chelator anti-Alzheimer drug, M30. Curr. Alzheimer Res. 2010;7:300&#x2013;306. doi: 10.2174/156720510791162403.</Citation><ArticleIdList><ArticleId IdType="doi">10.2174/156720510791162403</ArticleId><ArticleId IdType="pubmed">20043814</ArticleId></ArticleIdList></Reference><Reference><Citation>Gal S., Fridkin M., Amit T., Zheng H., Youdim M.B. M30, a novel multifunctional neuroprotective drug with potent iron chelating and brain selective monoamine oxidase-ab inhibitory activity for Parkinson&#x2019;s disease. J. Neural. Transm. Suppl. 2006:447&#x2013;456. doi: 10.1007/978-3-211-45295-0_68.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-211-45295-0_68</ArticleId><ArticleId IdType="pubmed">17017567</ArticleId></ArticleIdList></Reference><Reference><Citation>Avramovich-Tirosh Y., Amit T., Bar-Am O., Weinreb O., Youdim M.B. Physiological and pathological aspects of Abeta in iron homeostasis via 5&#x2019;UTR in the APP mRNA and the therapeutic use of iron-chelators. BMC Neurosci. 2008;9((Suppl. S2)):S2. doi: 10.1186/1471-2202-9-S2-S2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2202-9-S2-S2</ArticleId><ArticleId IdType="pmc">PMC2604902</ArticleId><ArticleId IdType="pubmed">19090990</ArticleId></ArticleIdList></Reference><Reference><Citation>Mechlovich D., Amit T., Mandel S.A., Bar-Am O., Bloch K., Vardi P., Youdim M.B. The novel multifunctional, iron-chelating drugs M30 and HLA20 protect pancreatic beta-cell lines from oxidative stress damage. J. Pharmacol. Exp. Ther. 2010;333:874&#x2013;882. doi: 10.1124/jpet.109.164269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/jpet.109.164269</ArticleId><ArticleId IdType="pubmed">20237072</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu W., Xie W., Pan T., Xu P., Fridkin M., Zheng H., Jankovic J., Youdim M.B., Le W. Prevention and restoration of lactacystin-induced nigrostriatal dopamine neuron degeneration by novel brain-permeable iron chelators. FASEB J. 2007;21:3835&#x2013;3844. doi: 10.1096/fj.07-8386com.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.07-8386com</ArticleId><ArticleId IdType="pubmed">17690154</ArticleId></ArticleIdList></Reference><Reference><Citation>Morris R. Developments of a water-maze procedure for studying spatial learning in the rat. J. Neurosci. Methods. 1984;11:47&#x2013;60. doi: 10.1016/0165-0270(84)90007-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0165-0270(84)90007-4</ArticleId><ArticleId IdType="pubmed">6471907</ArticleId></ArticleIdList></Reference><Reference><Citation>Collette F., Van der Linden M., Salmon E. Executive dysfunction in Alzheimer&#x2019;s disease. Cortex. 1999;35:57&#x2013;72. doi: 10.1016/S0010-9452(08)70785-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0010-9452(08)70785-8</ArticleId><ArticleId IdType="pubmed">10213534</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolb B., Mackintosh A., Whishaw I.Q., Sutherland R.J. Evidence for anatomical but not functional asymmetry in the hemidecorticate rat. Behav. Neurosci. 1984;98:44&#x2013;58. doi: 10.1037/0735-7044.98.1.44.</Citation><ArticleIdList><ArticleId IdType="doi">10.1037/0735-7044.98.1.44</ArticleId><ArticleId IdType="pubmed">6538091</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisoni G.B., Laakso M.P., Beltramello A., Geroldi C., Bianchetti A., Soininen H., Trabucchi M. Hippocampal and entorhinal cortex atrophy in frontotemporal dementia and Alzheimer&#x2019;s disease. Neurology. 1999;52:91&#x2013;100. doi: 10.1212/WNL.52.1.91.</Citation><ArticleIdList><ArticleId IdType="doi">10.1212/WNL.52.1.91</ArticleId><ArticleId IdType="pubmed">9921854</ArticleId></ArticleIdList></Reference><Reference><Citation>Azzouz M., Ralph G.S., Storkebaum E., Walmsley L.E., Mitrophanous K.A., Kingsman S.M., Carmeliet P., Mazarakis N.D. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature. 2004;429:413&#x2013;417. doi: 10.1038/nature02544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02544</ArticleId><ArticleId IdType="pubmed">15164063</ArticleId></ArticleIdList></Reference><Reference><Citation>Ding Y., Qiao A., Wang Z., Goodwin J.S., Lee E.S., Block M.L., Allsbrook M., McDonald M.P., Fan G.H. Retinoic acid attenuates beta-amyloid deposition and rescues memory deficits in an Alzheimer&#x2019;s disease transgenic mouse model. J. Neurosci. 2008;28:11622&#x2013;11634. doi: 10.1523/JNEUROSCI.3153-08.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.3153-08.2008</ArticleId><ArticleId IdType="pmc">PMC3844785</ArticleId><ArticleId IdType="pubmed">18987198</ArticleId></ArticleIdList></Reference><Reference><Citation>Gengler S., Hamilton A., Holscher C. Synaptic plasticity in the hippocampus of a APP/PS1 mouse model of Alzheimer&#x2019;s disease is impaired in old but not young mice. PLoS ONE. 2010;5:e9764. doi: 10.1371/journal.pone.0009764.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0009764</ArticleId><ArticleId IdType="pmc">PMC2842299</ArticleId><ArticleId IdType="pubmed">20339537</ArticleId></ArticleIdList></Reference><Reference><Citation>Rogers D.C., Peters J., Martin J.E., Ball S., Nicholson S.J., Witherden A.S., Hafezparast M., Latcham J., Robinson T.L., Quilter C.A., et al. SHIRPA, a protocol for behavioral assessment: Validation for longitudinal study of neurological dysfunction in mice. Neurosci. Lett. 2001;306:89&#x2013;92. doi: 10.1016/S0304-3940(01)01885-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0304-3940(01)01885-7</ArticleId><ArticleId IdType="pubmed">11403965</ArticleId></ArticleIdList></Reference><Reference><Citation>Chintala S., Novak E.K., Spernyak J.A., Mazurchuk R., Torres G., Patel S., Busch K., Meeder B.A., Horowitz J.M., Vaughan M.M., et al. The Vps33a gene regulates behavior and cerebellar Purkinje cell number. Brain Res. 2009;1266:18&#x2013;28. doi: 10.1016/j.brainres.2009.02.035.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2009.02.035</ArticleId><ArticleId IdType="pmc">PMC4677676</ArticleId><ArticleId IdType="pubmed">19254700</ArticleId></ArticleIdList></Reference><Reference><Citation>Cashman N.R., Durham H.D., Blusztajn J.K., Oda K., Tabira T., Shaw I.T., Dahrouge S., Antel J.P. Neuroblastoma x spinal cord (NSC) hybrid cell lines resemble developing motor neurons. Dev. Dyn. 1992;194:209&#x2013;221. doi: 10.1002/aja.1001940306.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/aja.1001940306</ArticleId><ArticleId IdType="pubmed">1467557</ArticleId></ArticleIdList></Reference><Reference><Citation>Pantopoulos K. Iron metabolism and the IRE/IRP regulatory system: An update. Ann. N. Y. Acad. Sci. 2004;1012:1&#x2013;13. doi: 10.1196/annals.1306.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1306.001</ArticleId><ArticleId IdType="pubmed">15105251</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiq A., Ayoub I.A., Chavez J.C., Aminova L., Shah S., LaManna J.C., Patton S.M., Connor J.R., Cherny R.A., Volitakis I., et al. Hypoxia-inducible factor prolyl 4-hydroxylase inhibition. A target for neuroprotection in the central nervous system. J. Biol. Chem. 2005;280:41732&#x2013;41743. doi: 10.1074/jbc.M504963200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M504963200</ArticleId><ArticleId IdType="pmc">PMC2586128</ArticleId><ArticleId IdType="pubmed">16227210</ArticleId></ArticleIdList></Reference><Reference><Citation>Semenza G.L. Expression of hypoxia-inducible factor 1: Mechanisms and consequences. Biochem. Pharmacol. 2000;59:47&#x2013;53. doi: 10.1016/S0006-2952(99)00292-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0006-2952(99)00292-0</ArticleId><ArticleId IdType="pubmed">10605934</ArticleId></ArticleIdList></Reference><Reference><Citation>Bruick R.K. Oxygen sensing in the hypoxic response pathway: Regulation of the hypoxia-inducible transcription factor. Genes Dev. 2003;17:2614&#x2013;2623. doi: 10.1101/gad.1145503.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/gad.1145503</ArticleId><ArticleId IdType="pubmed">14597660</ArticleId></ArticleIdList></Reference><Reference><Citation>Blancher C., Moore J.W., Robertson N., Harris A.L. Effects of ras and von Hippel-Lindau (VHL) gene mutations on hypoxia-inducible factor (HIF)-1alpha, HIF-2alpha, and vascular endothelial growth factor expression and their regulation by the phosphatidylinositol 3&#x2032;-kinase/Akt signaling pathway. Cancer Res. 2001;61:7349&#x2013;7355.</Citation><ArticleIdList><ArticleId IdType="pubmed">11585776</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang B.H., Jiang G., Zheng J.Z., Lu Z., Hunter T., Vogt P.K. Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1. Cell. Growth Differ. 2001;12:363&#x2013;369.</Citation><ArticleIdList><ArticleId IdType="pubmed">11457733</ArticleId></ArticleIdList></Reference><Reference><Citation>Forde J.E., Dale T.C. Glycogen synthase kinase 3: A key regulator of cellular fate. Cell. Mol. Life Sci. 2007;64:1930&#x2013;1944. doi: 10.1007/s00018-007-7045-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-007-7045-7</ArticleId><ArticleId IdType="pubmed">17530463</ArticleId></ArticleIdList></Reference><Reference><Citation>Matusica D., Fenech M.P., Rogers M.L., Rush R.A. Characterization and use of the NSC-34 cell line for study of neurotrophin receptor trafficking. J. Neurosci. Res. 2008;86:553&#x2013;565. doi: 10.1002/jnr.21507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.21507</ArticleId><ArticleId IdType="pubmed">17896795</ArticleId></ArticleIdList></Reference><Reference><Citation>Thelander L., Reichard P. Reduction of ribonucleotides. Annu. Rev. Biochem. 1979;48:133&#x2013;158. doi: 10.1146/annurev.bi.48.070179.001025.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.bi.48.070179.001025</ArticleId><ArticleId IdType="pubmed">382982</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda E., Weber G. Role of ribonucleotide reductase in expression in the neoplastic program. Life Sci. 1981;28:1007&#x2013;1014. doi: 10.1016/0024-3205(81)90746-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0024-3205(81)90746-3</ArticleId><ArticleId IdType="pubmed">7012518</ArticleId></ArticleIdList></Reference><Reference><Citation>Nurtjahja-Tjendraputra E., Fu D., Phang J.M., Richardson D.R. Iron chelation regulates cyclin D1 expression via the proteasome: A link to iron deficiency-mediated growth suppression. Blood. 2007;109:4045&#x2013;4054. doi: 10.1182/blood-2006-10-047753.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2006-10-047753</ArticleId><ArticleId IdType="pubmed">17197429</ArticleId></ArticleIdList></Reference><Reference><Citation>Sweatt J.D. The neuronal MAP kinase cascade: A biochemical signal integration system subserving synaptic plasticity and memory. J. Neurochem. 2001;76:1&#x2013;10. doi: 10.1046/j.1471-4159.2001.00054.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2001.00054.x</ArticleId><ArticleId IdType="pubmed">11145972</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyosseva S.V. Mitogen-activated protein kinase signaling. Int. Rev. Neurobiol. 2004;59:201&#x2013;220. doi: 10.1016/S0074-7742(04)59008-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0074-7742(04)59008-6</ArticleId><ArticleId IdType="pubmed">15006489</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh A.T., Bhattacharyya R.S., Radeff J.M., Stern P.H. Regulation of parathyroid hormone-stimulated phospholipase D in UMR-106 cells by calcium, MAP kinase, and small G proteins. J. Bone Miner. Res. 2003;18:1453&#x2013;1460. doi: 10.1359/jbmr.2003.18.8.1453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1359/jbmr.2003.18.8.1453</ArticleId><ArticleId IdType="pubmed">12929934</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenberger C., Mandriota S., Jurgensen J.S., Wiesener M.S., Horstrup J.H., Frei U., Ratcliffe P.J., Maxwell P.H., Bachmann S., Eckardt K.U. Expression of hypoxia-inducible factor-1alpha and -2alpha in hypoxic and ischemic rat kidneys. J. Am. Soc. Nephrol. 2002;13:1721&#x2013;1732. doi: 10.1097/01.ASN.0000017223.49823.2A.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ASN.0000017223.49823.2A</ArticleId><ArticleId IdType="pubmed">12089367</ArticleId></ArticleIdList></Reference><Reference><Citation>Siddiq A., Aminova L.R., Ratan R.R. Hypoxia inducible factor prolyl 4-hydroxylase enzymes: Center stage in the battle against hypoxia, metabolic compromise and oxidative stress. Neurochem. Res. 2007;32:931&#x2013;946. doi: 10.1007/s11064-006-9268-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-006-9268-7</ArticleId><ArticleId IdType="pmc">PMC2576999</ArticleId><ArticleId IdType="pubmed">17342411</ArticleId></ArticleIdList></Reference><Reference><Citation>Naoi M., Maruyama W. Functional mechanism of neuroprotection by inhibitors of type B monoamine oxidase in Parkinson&#x2019;s disease. Expert. Rev. Neurother. 2009;9:1233&#x2013;1250. doi: 10.1586/ern.09.68.</Citation><ArticleIdList><ArticleId IdType="doi">10.1586/ern.09.68</ArticleId><ArticleId IdType="pubmed">19673610</ArticleId></ArticleIdList></Reference><Reference><Citation>Moolman D.L., Vitolo O.V., Vonsattel J.P., Shelanski M.L. Dendrite and dendritic spine alterations in Alzheimer models. J. Neurocytol. 2004;33:377&#x2013;387. doi: 10.1023/B:NEUR.0000044197.83514.64.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/B:NEUR.0000044197.83514.64</ArticleId><ArticleId IdType="pubmed">15475691</ArticleId></ArticleIdList></Reference><Reference><Citation>Trinchese F., Liu S., Battaglia F., Walter S., Mathews P.M., Arancio O. Progressive age-related development of Alzheimer-like pathology in APP/PS1 mice. Ann. Neurol. 2004;55:801&#x2013;814. doi: 10.1002/ana.20101.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ana.20101</ArticleId><ArticleId IdType="pubmed">15174014</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky J.L., Slunt H.H., Ratovitski T., Jenkins N.A., Copeland N.G., Borchelt D.R. Co-expression of multiple transgenes in mouse CNS: A comparison of strategies. Biomol. Eng. 2001;17:157&#x2013;165. doi: 10.1016/S1389-0344(01)00067-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1389-0344(01)00067-3</ArticleId><ArticleId IdType="pubmed">11337275</ArticleId></ArticleIdList></Reference><Reference><Citation>Jankowsky J.L., Fadale D.J., Anderson J., Xu G.M., Gonzales V., Jenkins N.A., Copeland N.G., Lee M.K., Younkin L.H., Wagner S.L., et al. Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: Evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 2004;13:159&#x2013;170. doi: 10.1093/hmg/ddh019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/hmg/ddh019</ArticleId><ArticleId IdType="pubmed">14645205</ArticleId></ArticleIdList></Reference><Reference><Citation>Knobloch M., Mansuy I.M. Dendritic spine loss and synaptic alterations in Alzheimer&#x2019;s disease. Mol. Neurobiol. 2008;37:73&#x2013;82. doi: 10.1007/s12035-008-8018-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12035-008-8018-z</ArticleId><ArticleId IdType="pubmed">18438727</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan S.D., Chen X., Fu J., Chen M., Zhu H., Roher A., Slattery T., Zhao L., Nagashima M., Morser J., et al. RAGE and amyloid-beta peptide neurotoxicity in Alzheimer&#x2019;s disease. Nature. 1996;382:685&#x2013;691. doi: 10.1038/382685a0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/382685a0</ArticleId><ArticleId IdType="pubmed">8751438</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindowski K., Bretteville A., Leroy K., Begard S., Brion J.P., Hamdane M., Buee L. Alzheimer&#x2019;s disease-like tau neuropathology leads to memory deficits and loss of functional synapses in a novel mutated tau transgenic mouse without any motor deficits. Am. J. Pathol. 2006;169:599&#x2013;616. doi: 10.2353/ajpath.2006.060002.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2006.060002</ArticleId><ArticleId IdType="pmc">PMC1698785</ArticleId><ArticleId IdType="pubmed">16877359</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-Am O., Amit T., Weinreb O., Youdim M.B., Mandel S. Propargylamine containing compounds as modulators of proteolytic cleavage of amyloid-beta protein precursor: Involvement of MAPK and PKC activation. J. Alzheimers Dis. 2010;21:361&#x2013;371. doi: 10.3233/JAD-2010-100150.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-100150</ArticleId><ArticleId IdType="pubmed">20555137</ArticleId></ArticleIdList></Reference><Reference><Citation>Yogev-Falach M., Amit T., Bar-Am O., Weinstock M., Youdim M.B. Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline. FASEB J. 2002;16:1674&#x2013;1676. doi: 10.1096/fj.02-0198fje.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.02-0198fje</ArticleId><ArticleId IdType="pubmed">12206996</ArticleId></ArticleIdList></Reference><Reference><Citation>Jomova K., Vondrakova D., Lawson M., Valko M. Metals, oxidative stress and neurodegenerative disorders. Mol. Cell. Biochem. 2010;345:91&#x2013;104. doi: 10.1007/s11010-010-0563-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11010-010-0563-x</ArticleId><ArticleId IdType="pubmed">20730621</ArticleId></ArticleIdList></Reference><Reference><Citation>Dumont M., Beal M.F. Neuroprotective strategies involving ROS in Alzheimer disease. Free Radic. Biol. Med. 2011;51:1014&#x2013;1026. doi: 10.1016/j.freeradbiomed.2010.11.026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.freeradbiomed.2010.11.026</ArticleId><ArticleId IdType="pmc">PMC3070183</ArticleId><ArticleId IdType="pubmed">21130159</ArticleId></ArticleIdList></Reference><Reference><Citation>Engel T., Hernandez F., Avila J., Lucas J.J. Full reversal of Alzheimer&#x2019;s disease-like phenotype in a mouse model with conditional overexpression of glycogen synthase kinase-3. J. Neurosci. 2006;26:5083&#x2013;5090. doi: 10.1523/JNEUROSCI.0604-06.2006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1523/JNEUROSCI.0604-06.2006</ArticleId><ArticleId IdType="pmc">PMC6674262</ArticleId><ArticleId IdType="pubmed">16687499</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez F., Borrell J., Guaza C., Avila J., Lucas J.J. Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J. Neurochem. 2002;83:1529&#x2013;1533. doi: 10.1046/j.1471-4159.2002.01269.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1471-4159.2002.01269.x</ArticleId><ArticleId IdType="pubmed">12472906</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu F., Su Y., Li B., Zhou Y., Ryder J., Gonzalez-DeWhitt P., May P.C., Ni B. Regulation of amyloid precursor protein (APP) phosphorylation and processing by p35/Cdk5 and p25/Cdk5. FEBS Lett. 2003;547:193&#x2013;196. doi: 10.1016/S0014-5793(03)00714-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0014-5793(03)00714-2</ArticleId><ArticleId IdType="pubmed">12860412</ArticleId></ArticleIdList></Reference><Reference><Citation>Wen Y., Yu W.H., Maloney B., Bailey J., Ma J., Marie I., Maurin T., Wang L., Figueroa H., Herman M., et al. Transcriptional regulation of beta-secretase by p25/cdk5 leads to enhanced amyloidogenic processing. Neuron. 2008;57:680&#x2013;690. doi: 10.1016/j.neuron.2008.02.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuron.2008.02.024</ArticleId><ArticleId IdType="pmc">PMC2329816</ArticleId><ArticleId IdType="pubmed">18341989</ArticleId></ArticleIdList></Reference><Reference><Citation>Calhoun M.E., Wiederhold K.H., Abramowski D., Phinney A.L., Probst A., Sturchler-Pierrat C., Staufenbiel M., Sommer B., Jucker M. Neuron loss in APP transgenic mice. Nature. 1998;395:755&#x2013;756. doi: 10.1038/27351.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/27351</ArticleId><ArticleId IdType="pubmed">9796810</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreb O., Amit T., Bar-Am O., Youdim M.B. Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: New insights and implications for therapy. Ann. N. Y. Acad. Sci. 2007;1122:155&#x2013;168. doi: 10.1196/annals.1403.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1196/annals.1403.011</ArticleId><ArticleId IdType="pubmed">18077571</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizuta I., Ohta M., Ohta K., Nishimura M., Mizuta E., Hayashi K., Kuno S. Selegiline and desmethylselegiline stimulate NGF, BDNF, and GDNF synthesis in cultured mouse astrocytes. Biochem. Biophys. Res. Commun. 2000;279:751&#x2013;755. doi: 10.1006/bbrc.2000.4037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.2000.4037</ArticleId><ArticleId IdType="pubmed">11162424</ArticleId></ArticleIdList></Reference><Reference><Citation>Kupershmidt L., Weinreb O., Amit T., Mandel S., Bar-Am O., Youdim M.B. Novel molecular targets of the neuroprotective/neurorescue multimodal iron chelating drug M30 in the mouse brain. Neuroscience. 2011;189:345&#x2013;358. doi: 10.1016/j.neuroscience.2011.03.040.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2011.03.040</ArticleId><ArticleId IdType="pubmed">21570450</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu T., Pan Y., Kao S.Y., Li C., Kohane I., Chan J., Yankner B.A. Gene regulation and DNA damage in the ageing human brain. Nature. 2004;429:883&#x2013;891. doi: 10.1038/nature02661.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature02661</ArticleId><ArticleId IdType="pubmed">15190254</ArticleId></ArticleIdList></Reference><Reference><Citation>Yankner B.A., Lu T., Loerch P. The aging brain. Annu. Rev. Pathol. 2008;3:41&#x2013;66. doi: 10.1146/annurev.pathmechdis.2.010506.092044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.pathmechdis.2.010506.092044</ArticleId><ArticleId IdType="pubmed">18039130</ArticleId></ArticleIdList></Reference><Reference><Citation>Harman A.W., Adamson G.M., Shaw S.G. Protection from oxidative damage in mouse liver cells. Toxicol. Lett. 1992;64&#x2013;65:581&#x2013;587. doi: 10.1016/0378-4274(92)90235-C.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0378-4274(92)90235-C</ArticleId><ArticleId IdType="pubmed">1471211</ArticleId></ArticleIdList></Reference><Reference><Citation>Poon H.F., Calabrese V., Calvani M., Butterfield D.A. Proteomics analyses of specific protein oxidation and protein expression in aged rat brain and its modulation by L-acetylcarnitine: Insights into the mechanisms of action of this proposed therapeutic agent for CNS disorders associated with oxidative stress. Antioxid. Redox Signal. 2006;8:381&#x2013;394. doi: 10.1089/ars.2006.8.381.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2006.8.381</ArticleId><ArticleId IdType="pubmed">16677085</ArticleId></ArticleIdList></Reference><Reference><Citation>de Lima M.N., Dias C.P., Torres J.P., Dornelles A., Garcia V.A., Scalco F.S., Guimaraes M.R., Petry R.C., Bromberg E., Constantino L., et al. Reversion of age-related recognition memory impairment by iron chelation in rats. Neurobiol. Aging. 2008;29:1052&#x2013;1059. doi: 10.1016/j.neurobiolaging.2007.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2007.02.006</ArticleId><ArticleId IdType="pubmed">17346856</ArticleId></ArticleIdList></Reference><Reference><Citation>Binda C., Hubalek F., Li M., Herzig Y., Sterling J., Edmondson D.E., Mattevi A. Crystal structures of monoamine oxidase B in complex with four inhibitors of the N-propargylaminoindan class. J. Med. Chem. 2004;47:1767&#x2013;1774. doi: 10.1021/jm031087c.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/jm031087c</ArticleId><ArticleId IdType="pubmed">15027868</ArticleId></ArticleIdList></Reference><Reference><Citation>Shemyakov S.E. Monoamine oxidase activity, lipid peroxidation, and morphological changes in human hypothalamus during aging. Bull. Exp. Biol. Med. 2001;131:586&#x2013;588. doi: 10.1023/A:1012371106766.</Citation><ArticleIdList><ArticleId IdType="doi">10.1023/A:1012371106766</ArticleId><ArticleId IdType="pubmed">11586414</ArticleId></ArticleIdList></Reference><Reference><Citation>Irwin I., Finnegan K.T., Delanney L.E., Di Monte D., Langston J.W. The relationships between aging, monoamine oxidase, striatal dopamine and the effects of MPTP in C57BL/6 mice: A critical reassessment. Brain Res. 1992;572:224&#x2013;231. doi: 10.1016/0006-8993(92)90473-M.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-8993(92)90473-M</ArticleId><ArticleId IdType="pubmed">1611516</ArticleId></ArticleIdList></Reference><Reference><Citation>Saura J., Richards J.G., Mahy N. Differential age-related changes of MAO-A and MAO-B in mouse brain and peripheral organs. Neurobiol. Aging. 1994;15:399&#x2013;408. doi: 10.1016/0197-4580(94)90071-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0197-4580(94)90071-X</ArticleId><ArticleId IdType="pubmed">7969716</ArticleId></ArticleIdList></Reference><Reference><Citation>Carrillo M.C., Minami C., Kitani K., Maruyama W., Ohashi K., Yamamoto T., Naoi M., Kanai S., Youdim M.B. Enhancing effect of rasagiline on superoxide dismutase and catalase activities in the dopaminergic system in the rat. Life Sci. 2000;67:577&#x2013;585. doi: 10.1016/S0024-3205(00)00643-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0024-3205(00)00643-3</ArticleId><ArticleId IdType="pubmed">10993123</ArticleId></ArticleIdList></Reference><Reference><Citation>Knoll J. (-)Deprenyl (selegiline), a catecholaminergic activity enhancer (CAE) substance acting in the brain. Pharmacol. Toxicol. 1998;82:57&#x2013;66. doi: 10.1111/j.1600-0773.1998.tb01399.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1600-0773.1998.tb01399.x</ArticleId><ArticleId IdType="pubmed">9498233</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitani K., Miyasaka K., Kanai S., Carrillo M.C., Ivy G.O. Upregulation of antioxidant enzyme activities by deprenyl. Implications for life span extension. Ann. N. Y. Acad. Sci. 1996;786:391&#x2013;409. doi: 10.1111/j.1749-6632.1996.tb39079.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.1996.tb39079.x</ArticleId><ArticleId IdType="pubmed">8687037</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitani K., Kanai S., Ivy G.O., Carrillo M.C. Assessing the effects of deprenyl on longevity and antioxidant defenses in different animal models. Ann. N. Y. Acad. Sci. 1998;854:291&#x2013;306. doi: 10.1111/j.1749-6632.1998.tb09910.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1749-6632.1998.tb09910.x</ArticleId><ArticleId IdType="pubmed">9928438</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitani K., Kanai S., Ivy G.O., Carrillo M.C. Pharmacological modifications of endogenous antioxidant enzymes with special reference to the effects of deprenyl: A possible antioxidant strategy. Mech. Ageing Dev. 1999;111:211&#x2013;221. doi: 10.1016/S0047-6374(99)00065-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0047-6374(99)00065-2</ArticleId><ArticleId IdType="pubmed">10656538</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreb O., Drigues N., Sagi Y., Reznick A.Z., Amit T., Youdim M.B. The application of proteomics and genomics to the study of age-related neurodegeneration and neuroprotection. Antioxid. Redox Signal. 2007;9:169&#x2013;179. doi: 10.1089/ars.2007.9.169.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2007.9.169</ArticleId><ArticleId IdType="pubmed">17115941</ArticleId></ArticleIdList></Reference><Reference><Citation>Reznichenko L., Amit T., Zheng H., Avramovich-Tirosh Y., Youdim M.B., Weinreb O., Mandel S. Reduction of iron-regulated amyloid precursor protein and beta-amyloid peptide by (-)-epigallocatechin-3-gallate in cell cultures: Implications for iron chelation in Alzheimer&#x2019;s disease. J. Neurochem. 2006;97:527&#x2013;536. doi: 10.1111/j.1471-4159.2006.03770.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2006.03770.x</ArticleId><ArticleId IdType="pubmed">16539659</ArticleId></ArticleIdList></Reference><Reference><Citation>Zou L., Yang R., Zhang P., Dai Y. The enhancement of amyloid precursor protein and beta-site amyloid cleavage enzyme 1 interaction: Amyloid-beta production with aging. Int. J. Mol. Med. 2010;25:401&#x2013;407. doi: 10.3892/ijmm_00000358.</Citation><ArticleIdList><ArticleId IdType="doi">10.3892/ijmm_00000358</ArticleId><ArticleId IdType="pubmed">20127045</ArticleId></ArticleIdList></Reference><Reference><Citation>Banks W.A., Farr S.A., Morley J.E., Wolf K.M., Geylis V., Steinitz M. Anti-amyloid beta protein antibody passage across the blood-brain barrier in the SAMP8 mouse model of Alzheimer&#x2019;s disease: An age-related selective uptake with reversal of learning impairment. Exp. Neurol. 2007;206:248&#x2013;256. doi: 10.1016/j.expneurol.2007.05.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2007.05.005</ArticleId><ArticleId IdType="pmc">PMC2080786</ArticleId><ArticleId IdType="pubmed">17582399</ArticleId></ArticleIdList></Reference><Reference><Citation>Head E., Moffat K., Das P., Sarsoza F., Poon W.W., Landsberg G., Cotman C.W., Murphy M.P. Beta-amyloid deposition and tau phosphorylation in clinically characterized aged cats. Neurobiol. Aging. 2005;26:749&#x2013;763. doi: 10.1016/j.neurobiolaging.2004.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neurobiolaging.2004.06.015</ArticleId><ArticleId IdType="pubmed">15708450</ArticleId></ArticleIdList></Reference><Reference><Citation>Preston J.E. Ageing choroid plexus-cerebrospinal fluid system. Microsc. Res. Tech. 2001;52:31&#x2013;37. doi: 10.1002/1097-0029(20010101)52:1&lt;31::AID-JEMT5&gt;3.0.CO;2-T.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/1097-0029(20010101)52:1&lt;31::AID-JEMT5&gt;3.0.CO;2-T</ArticleId><ArticleId IdType="pubmed">11135446</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaucher E., Aumont N., Pearson D., Rowe W., Poirier J., Kar S. Amyloid beta peptide levels and its effects on hippocampal acetylcholine release in aged, cognitively-impaired and -unimpaired rats. J. Chem. Neuroanat. 2001;21:323&#x2013;329. doi: 10.1016/S0891-0618(01)00120-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0891-0618(01)00120-X</ArticleId><ArticleId IdType="pubmed">11429273</ArticleId></ArticleIdList></Reference><Reference><Citation>Reddy P.H., Manczak M., Mao P., Calkins M.J., Reddy A.P., Shirendeb U. Amyloid-beta and mitochondria in aging and Alzheimer&#x2019;s disease: Implications for synaptic damage and cognitive decline. J. Alzheimers Dis. 2010;20((Suppl. S2)):S499&#x2013;S512. doi: 10.3233/JAD-2010-100504.</Citation><ArticleIdList><ArticleId IdType="doi">10.3233/JAD-2010-100504</ArticleId><ArticleId IdType="pmc">PMC3059092</ArticleId><ArticleId IdType="pubmed">20413847</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y., Zhou W., Tong Y., He G., Song W. Control of APP processing and Abeta generation level by BACE1 enzymatic activity and transcription. FASEB J. 2006;20:285&#x2013;292. doi: 10.1096/fj.05-4986com.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.05-4986com</ArticleId><ArticleId IdType="pubmed">16449801</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassar R., Bennett B.D., Babu-Khan S., Kahn S., Mendiaz E.A., Denis P., Teplow D.B., Ross S., Amarante P., Loeloff R., et al. Beta-secretase cleavage of Alzheimer&#x2019;s amyloid precursor protein by the transmembrane aspartic protease BACE. Science. 1999;286:735&#x2013;741. doi: 10.1126/science.286.5440.735.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.286.5440.735</ArticleId><ArticleId IdType="pubmed">10531052</ArticleId></ArticleIdList></Reference><Reference><Citation>Durham H.D., Dahrouge S., Cashman N.R. Evaluation of the spinal cord neuron X neuroblastoma hybrid cell line NSC-34 as a model for neurotoxicity testing. Neurotoxicology. 1993;14:387&#x2013;395.</Citation><ArticleIdList><ArticleId IdType="pubmed">7909362</ArticleId></ArticleIdList></Reference><Reference><Citation>Cassina P., Peluffo H., Pehar M., Martinez-Palma L., Ressia A., Beckman J.S., Estevez A.G., Barbeito L. Peroxynitrite triggers a phenotypic transformation in spinal cord astrocytes that induces motor neuron apoptosis. J. Neurosci. Res. 2002;67:21&#x2013;29. doi: 10.1002/jnr.10107.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jnr.10107</ArticleId><ArticleId IdType="pubmed">11754077</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin L.J. Transgenic mice with human mutant genes causing Parkinson&#x2019;s disease and amyotrophic lateral sclerosis provide common insight into mechanisms of motor neuron selective vulnerability to degeneration. Rev. Neurosci. 2007;18:115&#x2013;136. doi: 10.1515/REVNEURO.2007.18.2.115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/REVNEURO.2007.18.2.115</ArticleId><ArticleId IdType="pubmed">17593875</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar-Am O., Yogev-Falach M., Amit T., Sagi Y., Youdim M.B. Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo. J. Neurochem. 2004;89:1119&#x2013;1125. doi: 10.1111/j.1471-4159.2004.02425.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2004.02425.x</ArticleId><ArticleId IdType="pubmed">15147504</ArticleId></ArticleIdList></Reference><Reference><Citation>Weinreb O., Bar-Am O., Amit T., Chillag-Talmor O., Youdim M.B. Neuroprotection via pro-survival protein kinase C isoforms associated with Bcl-2 family members. FASEB J. 2004;18:1471&#x2013;1473. doi: 10.1096/fj.04-1916fje.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.04-1916fje</ArticleId><ArticleId IdType="pubmed">15247150</ArticleId></ArticleIdList></Reference><Reference><Citation>Almli L.M., Hamrick S.E., Koshy A.A., Tauber M.G., Ferriero D.M. Multiple pathways of neuroprotection against oxidative stress and excitotoxic injury in immature primary hippocampal neurons. Brain Res. Dev. Brain Res. 2001;132:121&#x2013;129. doi: 10.1016/S0165-3806(01)00302-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0165-3806(01)00302-9</ArticleId><ArticleId IdType="pubmed">11744116</ArticleId></ArticleIdList></Reference><Reference><Citation>Belaiba R.S., Bonello S., Zahringer C., Schmidt S., Hess J., Kietzmann T., Gorlach A. Hypoxia up-regulates hypoxia-inducible factor-1alpha transcription by involving phosphatidylinositol 3-kinase and nuclear factor kappaB in pulmonary artery smooth muscle cells. Mol. Biol. Cell. 2007;18:4691&#x2013;4697. doi: 10.1091/mbc.e07-04-0391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1091/mbc.e07-04-0391</ArticleId><ArticleId IdType="pmc">PMC2096613</ArticleId><ArticleId IdType="pubmed">17898080</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiener C.M., Booth G., Semenza G.L. In vivo expression of mRNAs encoding hypoxia-inducible factor 1. Biochem. Biophys. Res. Commun. 1996;225:485&#x2013;488. doi: 10.1006/bbrc.1996.1199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/bbrc.1996.1199</ArticleId><ArticleId IdType="pubmed">8753788</ArticleId></ArticleIdList></Reference><Reference><Citation>Tolosa L., Mir M., Olmos G., Llado J. Vascular endothelial growth factor protects motoneurons from serum deprivation-induced cell death through phosphatidylinositol 3-kinase-mediated p38 mitogen-activated protein kinase inhibition. Neuroscience. 2009;158:1348&#x2013;1355. doi: 10.1016/j.neuroscience.2008.10.060.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neuroscience.2008.10.060</ArticleId><ArticleId IdType="pubmed">19041930</ArticleId></ArticleIdList></Reference><Reference><Citation>Lambrechts D., Storkebaum E., Morimoto M., Del-Favero J., Desmet F., Marklund S.L., Wyns S., Thijs V., Andersson J., van Marion I., et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death. Nat. Genet. 2003;34:383&#x2013;394. doi: 10.1038/ng1211.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ng1211</ArticleId><ArticleId IdType="pubmed">12847526</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau C., Devos D., Brunaud-Danel V., Defebvre L., Perez T., Destee A., Tonnel A.B., Lassalle P., Just N. Paradoxical response of VEGF expression to hypoxia in CSF of patients with ALS. J. Neurol. Neurosurg. Psychiatry. 2006;77:255&#x2013;257. doi: 10.1136/jnnp.2005.070904.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.2005.070904</ArticleId><ArticleId IdType="pmc">PMC2077591</ArticleId><ArticleId IdType="pubmed">16421133</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Den Bosch L., Storkebaum E., Vleminckx V., Moons L., Vanopdenbosch L., Scheveneels W., Carmeliet P., Robberecht W. Effects of vascular endothelial growth factor (VEGF) on motor neuron degeneration. Neurobiol. Dis. 2004;17:21&#x2013;28. doi: 10.1016/j.nbd.2004.06.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.nbd.2004.06.004</ArticleId><ArticleId IdType="pubmed">15350962</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen C., Pore N., Behrooz A., Ismail-Beigi F., Maity A. Regulation of glut1 mRNA by hypoxia-inducible factor-1. Interaction between H-ras and hypoxia. J. Biol. Chem. 2001;276:9519&#x2013;9525. doi: 10.1074/jbc.M010144200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M010144200</ArticleId><ArticleId IdType="pubmed">11120745</ArticleId></ArticleIdList></Reference><Reference><Citation>Semenza G.L., Roth P.H., Fang H.M., Wang G.L. Transcriptional regulation of genes encoding glycolytic enzymes by hypoxia-inducible factor 1. J. Biol. Chem. 1994;269:23757&#x2013;23763. doi: 10.1016/S0021-9258(17)31580-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(17)31580-6</ArticleId><ArticleId IdType="pubmed">8089148</ArticleId></ArticleIdList></Reference><Reference><Citation>Brand K.A., Hermfisse U. Aerobic glycolysis by proliferating cells: A protective strategy against reactive oxygen species. FASEB J. 1997;11:388&#x2013;395. doi: 10.1096/fasebj.11.5.9141507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fasebj.11.5.9141507</ArticleId><ArticleId IdType="pubmed">9141507</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulp K.S., Green S.L., Vulliet P.R. Iron deprivation inhibits cyclin-dependent kinase activity and decreases cyclin D/CDK4 protein levels in asynchronous MDA-MB-453 human breast cancer cells. Exp. Cell. Res. 1996;229:60&#x2013;68. doi: 10.1006/excr.1996.0343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/excr.1996.0343</ArticleId><ArticleId IdType="pubmed">8940249</ArticleId></ArticleIdList></Reference><Reference><Citation>Amit T., Avramovich-Tirosh Y., Youdim M.B., Mandel S. Targeting multiple Alzheimer&#x2019;s disease etiologies with multimodal neuroprotective and neurorestorative iron chelators. FASEB J. 2008;22:1296&#x2013;1305. doi: 10.1096/fj.07-8627rev.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.07-8627rev</ArticleId><ArticleId IdType="pubmed">18048580</ArticleId></ArticleIdList></Reference><Reference><Citation>Bar Am O., Amit T., Youdim M.B. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci. Lett. 2004;355:169&#x2013;172. doi: 10.1016/j.neulet.2003.10.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2003.10.067</ArticleId><ArticleId IdType="pubmed">14732458</ArticleId></ArticleIdList></Reference><Reference><Citation>Buck C.R., Seburn K.L., Cope T.C. Neurotrophin expression by spinal motoneurons in adult and developing rats. J. Comp. Neurol. 2000;416:309&#x2013;318. doi: 10.1002/(SICI)1096-9861(20000117)416:3&lt;309::AID-CNE3&gt;3.0.CO;2-U.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1096-9861(20000117)416:3&lt;309::AID-CNE3&gt;3.0.CO;2-U</ArticleId><ArticleId IdType="pubmed">10602090</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda O., Murakami M., Ino H., Yamazaki M., Koda M., Nakayama C., Moriya H. Effects of brain-derived neurotrophic factor (BDNF) on compression-induced spinal cord injury: BDNF attenuates down-regulation of superoxide dismutase expression and promotes up-regulation of myelin basic protein expression. J. Neuropathol. Exp. Neurol. 2002;61:142&#x2013;153. doi: 10.1093/jnen/61.2.142.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/jnen/61.2.142</ArticleId><ArticleId IdType="pubmed">11853017</ArticleId></ArticleIdList></Reference><Reference><Citation>Namiki J., Kojima A., Tator C.H. Effect of brain-derived neurotrophic factor, nerve growth factor, and neurotrophin-3 on functional recovery and regeneration after spinal cord injury in adult rats. J. Neurotrauma. 2000;17:1219&#x2013;1231. doi: 10.1089/neu.2000.17.1219.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/neu.2000.17.1219</ArticleId><ArticleId IdType="pubmed">11186234</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin D.X., Zou X.L., Luo W., Zhang W., Zhang H.T., Li X.L., Zhang H., Wang X.Y., Wang T.H. Expression of some neurotrophins in the spinal motoneurons after cord hemisection in adult rats. Neurosci. Lett. 2006;410:222&#x2013;227. doi: 10.1016/j.neulet.2006.10.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.neulet.2006.10.006</ArticleId><ArticleId IdType="pubmed">17055159</ArticleId></ArticleIdList></Reference><Reference><Citation>Bendotti C., Carri M.T. Lessons from models of SOD1-linked familial ALS. Trends Mol. Med. 2004;10:393&#x2013;400. doi: 10.1016/j.molmed.2004.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molmed.2004.06.009</ArticleId><ArticleId IdType="pubmed">15310460</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Q., Zhang X., Chen S., Zhang X., Zhang S., Youdium M., Le W. Prevention of motor neuron degeneration by novel iron chelators in SOD1(G93A) transgenic mice of amyotrophic lateral sclerosis. Neurodegener. Dis. 2011;8:310&#x2013;321. doi: 10.1159/000323469.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000323469</ArticleId><ArticleId IdType="pubmed">21346313</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y.X., Ding S.J., Xiao L., Guo W., Zhan Q. Desferoxamine preconditioning protects against cerebral ischemia in rats by inducing expressions of hypoxia inducible factor 1 alpha and erythropoietin. Neurosci. Bull. 2008;24:89&#x2013;95. doi: 10.1007/s12264-008-0089-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12264-008-0089-3</ArticleId><ArticleId IdType="pmc">PMC5552517</ArticleId><ArticleId IdType="pubmed">18369388</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang G.L., Semenza G.L. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: Implications for models of hypoxia signal transduction. Blood. 1993;82:3610&#x2013;3615. doi: 10.1182/blood.V82.12.3610.3610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V82.12.3610.3610</ArticleId><ArticleId IdType="pubmed">8260699</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaman K., Ryu H., Hall D., O&#x2019;Donovan K., Lin K.I., Miller M.P., Marquis J.C., Baraban J.M., Semenza G.L., Ratan R.R. Protection from oxidative stress-induced apoptosis in cortical neuronal cultures by iron chelators is associated with enhanced DNA binding of hypoxia-inducible factor-1 and ATF-1/CREB and increased expression of glycolytic enzymes, p21(waf1/cip1), and erythropoietin. J. Neurosci. 1999;19:9821&#x2013;9830.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6782985</ArticleId><ArticleId IdType="pubmed">10559391</ArticleId></ArticleIdList></Reference><Reference><Citation>Correia S.C., Moreira P.I. Hypoxia-inducible factor 1: A new hope to counteract neurodegeneration? J. Neurochem. 2010;112:1&#x2013;12. doi: 10.1111/j.1471-4159.2009.06443.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1471-4159.2009.06443.x</ArticleId><ArticleId IdType="pubmed">19845827</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharp F.R., Bernaudin M. HIF1 and oxygen sensing in the brain. Nat. Rev. Neurosci. 2004;5:437&#x2013;448. doi: 10.1038/nrn1408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrn1408</ArticleId><ArticleId IdType="pubmed">15152194</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy T.H., Schnaar R.L., Coyle J.T. Immature cortical neurons are uniquely sensitive to glutamate toxicity by inhibition of cystine uptake. FASEB J. 1990;4:1624&#x2013;1633. doi: 10.1096/fasebj.4.6.2180770.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fasebj.4.6.2180770</ArticleId><ArticleId IdType="pubmed">2180770</ArticleId></ArticleIdList></Reference><Reference><Citation>Prass K., Ruscher K., Karsch M., Isaev N., Megow D., Priller J., Scharff A., Dirnagl U., Meisel A. Desferrioxamine induces delayed tolerance against cerebral ischemia in vivo and in vitro. J. Cereb. Blood Flow Metab. 2002;22:520&#x2013;525. doi: 10.1097/00004647-200205000-00003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00004647-200205000-00003</ArticleId><ArticleId IdType="pubmed">11973424</ArticleId></ArticleIdList></Reference><Reference><Citation>Dongiovanni P., Valenti L., Ludovica Fracanzani A., Gatti S., Cairo G., Fargion S. Iron depletion by deferoxamine up-regulates glucose uptake and insulin signaling in hepatoma cells and in rat liver. Am. J. Pathol. 2008;172:738&#x2013;747. doi: 10.2353/ajpath.2008.070097.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2008.070097</ArticleId><ArticleId IdType="pmc">PMC2258266</ArticleId><ArticleId IdType="pubmed">18245813</ArticleId></ArticleIdList></Reference><Reference><Citation>Kitani K., Minami C., Maruyama W., Kanai S., Ivy G.O., Carrillo M.C. Advances in Research on Neurodegeneration. Springer; Berlin, Germany: 2000. Common properties for propargylamines of enhancing superoxide dismutase and catalase activities in the dopaminergic system in the rat: Implications for the life prolonging effect of (-)deprenyl; pp. 139&#x2013;156.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/978-3-7091-6301-6_9</ArticleId><ArticleId IdType="pubmed">11205136</ArticleId></ArticleIdList></Reference><Reference><Citation>Koh S.H., Kim S.H., Kwon H., Park Y., Kim K.S., Song C.W., Kim J., Kim M.H., Yu H.J., Henkel J.S., et al. Epigallocatechin gallate protects nerve growth factor differentiated PC12 cells from oxidative-radical-stress-induced apoptosis through its effect on phosphoinositide 3-kinase/Akt and glycogen synthase kinase-3. Brain Res. Mol. Brain Res. 2003;118:72&#x2013;81. doi: 10.1016/j.molbrainres.2003.07.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molbrainres.2003.07.003</ArticleId><ArticleId IdType="pubmed">14559356</ArticleId></ArticleIdList></Reference><Reference><Citation>Risbud M.V., Fertala J., Vresilovic E.J., Albert T.J., Shapiro I.M. Nucleus pulposus cells upregulate PI3K/Akt and MEK/ERK signaling pathways under hypoxic conditions and resist apoptosis induced by serum withdrawal. Spine. 2005;30:882&#x2013;889. doi: 10.1097/01.brs.0000159096.11248.6d.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.brs.0000159096.11248.6d</ArticleId><ArticleId IdType="pubmed">15834331</ArticleId></ArticleIdList></Reference><Reference><Citation>Sung S.M., Jung D.S., Kwon C.H., Park J.Y., Kang S.K., Kim Y.K. Hypoxia/reoxygenation stimulates proliferation through PKC-dependent activation of ERK and Akt in mouse neural progenitor cells. Neurochem. Res. 2007;32:1932&#x2013;1939. doi: 10.1007/s11064-007-9390-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11064-007-9390-1</ArticleId><ArticleId IdType="pubmed">17562163</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernhardt W.M., Warnecke C., Willam C., Tanaka T., Wiesener M.S., Eckardt K.U. Organ protection by hypoxia and hypoxia-inducible factors. Methods Enzymol. 2007;435:221&#x2013;245. doi: 10.1016/S0076-6879(07)35012-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0076-6879(07)35012-X</ArticleId><ArticleId IdType="pubmed">17998057</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>